

1 **Trends and Characteristics during 17 Years of Naloxone Distribution and Administration**
2 **through a Harm Reduction Program in Pittsburgh, Pennsylvania**

3

4 Short title: Naloxone distribution time trends

5

6 Nabarun Dasgupta^{1,3*}

7 Alice Bell²

8 Malcolm Visnich²

9 Maya Doe-Simkins³

10 Eliza Wheeler³

11 Adams L. Sibley¹

12 Maryalice Nocera¹

13 Amy E. Seitz⁴

14 Dorothy Chang⁴

15 Summer Barlow⁴

16 Zachary Dezman⁴

17 Jana McAninch⁴

18

19

20 1. University of North Carolina, Chapel Hill, North Carolina, USA

21 2. Prevention Point Pittsburgh, Pittsburgh, Pennsylvania, USA

22 3. Remedy Alliance For The People, Berkeley, California, USA

23 4. US Food and Drug Administration, Silver Spring, Maryland, USA

24

25 * Corresponding author

26 E-mail: nab@unc.edu (ND)

27

28

29 Abstract word count: 300/300

30 Manuscript word count: 14,439

31 Citation count: 86

32 Figure count: 13

33 Table count: 4

34 Supplemental material

35

37 **ABSTRACT**

38
39 **Objective:** Describe time trends during 17.6 years of community-based naloxone distribution.

40
41 **Methods:** Analysis of administrative records from a harm reduction program in Pittsburgh,
42 Pennsylvania, USA, collected during encounters for overdose education, naloxone dispensing
43 and refills. Monthly time trends were analyzed using segmented regression. Programmatic
44 context aided interpretation of quantitative findings. We also evaluated impacts of 2014 state
45 legislation loosening naloxone prescribing requirements and providing Good Samaritan
46 protections.

47
48 **Results:** From July 2005 to January 2023 there were 16,904 service encounters by 7,582
49 unique participants, resulting in 70,234 naloxone doses dispensed, with 5,521 overdose
50 response events (OREs), utilizing 8,756 naloxone doses. After legislation, new participants
51 increased from 10.4 to 65.9 per month. New participants tended to be older (46 vs. 37 years),
52 female (58% to 35%), White race, and more likely to be family/friends as opposed to people
53 who use drugs themselves. Consequently, ORE per participant fell from 1.46 to 0.47 in the year
54 after enactment. On average, 1.63 (95% CI: 1.60, 1.65) naloxone doses were administered per
55 ORE, which did not change substantially over 17 years ($\chi^2=0.28$, 3 df, $p=0.60$) during evolution
56 from prescription opioids, to heroin, to illicitly manufactured fentanyl. In 98.0% of OREs the
57 person who experienced overdose "was okay", i.e., survived. Emergency medical services were
58 called in 16% of OREs overall, but <7% since 2019. There were 106 more emesis events per
59 1,000 OREs with 4mg nasal spray compared to intramuscular injection; and 48 per 1,000 more
60 reports of anger. Titration of intramuscular naloxone was associated with lower rates of adverse
61 events.

62
63 **Conclusions:** While state legislation created the environment for expansion, reaching
64 previously underserved communities required intentional new programmatic development and
65 outreach. Long-term consistency of <2 doses per ORE, high survival rate, and robust utilization
66 all lend confidence in prioritizing naloxone distribution directly to people who use drugs and their
67 social networks.

68

69 INTRODUCTION

70 In the United States (US), fatal overdose rates have increased over the past four decades. The
71 characteristics have changed from heroin dominance in the early 1990s to prescription opioids
72 in the late 1990s and 2000s, to heroin again around 2013 [1,2]. By 2015, the emergence of non-
73 pharmaceutical fentanyl and analogues played the most prominent role in fatal overdoses, and
74 currently stimulant-opioid fatal overdoses are increasing [3,4]. After many years of unrelenting
75 increases, the latest national data appear to show a 3% decline in annual overdose deaths in
76 2023 [5,6]. However, at the state level the results are heterogeneous: some states posted 15%
77 reductions, and others showed marked increases.

78

79 Community-based distribution of the opioid overdose reversal agent, naloxone, has expanded
80 considerably since federal funding support in 2018 and is a critical strategy for preventing
81 fatalities [7]. Harm reduction programs train people who use drugs to recognize and respond to
82 opioid-induced respiratory depression. People who access these services, by the nature of their
83 ongoing drug use, are at the highest risk of overdose [8], yet there is a paucity of quantitative
84 data characterizing peer reversal behaviors, particularly as the drug supply landscape has
85 evolved. Specifically, in the context of community-based naloxone distribution, there are few
86 published studies detailing time trends of adverse events, formulation effects, titration practices,
87 changes during the COVID-19 pandemic, and infiltration of xylazine in the unregulated drug
88 supply. Over the last two decades, state laws have also evolved to reduce barriers to
89 community-based naloxone distribution. In the scientific literature, policy analyses of state laws
90 have lent support for this continued practice [9], localized evaluations have been published [10–
91 13], as have evaluations of barriers [14,15]. What has been not been adequately described is
92 the longitudinal evolution of harm reduction programs themselves. As harm reduction programs

93 become enduring and institutionalized with increased public health investment, it is imperative to
94 understand long-term programmatic trajectories, which can, in turn, inform future policy
95 decisions.

96

97 Specifically, there is limited documentation of how harm reduction programs adapt to changing
98 drug supply, laws, pharmaceutical formulations, and societal norms over an extended time.

99 Herein we describe trends and experiences over 17 years from one of the longest continuously
100 operating overdose prevention programs in the world, at Prevention Point Pittsburgh, a harm
101 reduction and syringe services program. With continuous data collection [16], this setting offers
102 a unique opportunity to understand long-term time trends in both community practice and
103 individual responses simultaneously.

104

105 Applying the Evidence-Making Intervention framework [17], this comprehensive manuscript
106 balances programmatic context with quantitative findings. The authors come from three
107 professional domains: harm reduction program staff, government and academic scientists, and
108 public health advocates. Some of the authors were the earliest innovators and implementors of
109 community-based naloxone distribution in the US [18–21]. Of note, Prevention Point Pittsburgh
110 has maintained institutional memory via staff retention; one co-author (AB) has been directing
111 the program in Pittsburgh for the entirety of the observation period and provided invaluable
112 canonical information on changes in service delivery. The length of the manuscript reflects
113 aspects that are of relevance to each of the three professional domains, and we encourage
114 readers to make use of section headings to follow the storyline that is of greatest interest.

115

116

117

118 **About Naloxone**

119
120 Naloxone is a mu-opioid receptor antagonist that displaces or prevents binding of opioid
121 agonists such as heroin, fentanyl, and morphine. It was first synthesized in 1961 by Jack
122 Fishman and Harold Blumberg. Naloxone was approved as a human prescription medication by
123 the US Food and Drug Administration (FDA) in 1971 to treat opioid-induced respiratory
124 depression (“overdose”), and is on the World Health Organization’s List of Essential Medicines
125 [22]. It reverses opioid-induced respiratory depression rapidly but may also precipitate
126 withdrawal in people who have opioid tolerance. Community-based naloxone distribution has
127 become widely accepted in the US as a means of secondary prevention of overdose deaths,
128 albeit with heterogeneity in enabling state governmental laws and policies [23].

129

130 **Brief History of Community Naloxone Distribution**

131 Prevention Point Pittsburgh started distributing naloxone in 2005, after being inspired by
132 formative work by the Chicago Recovery Alliance. Previously naloxone had been used
133 exclusively in hospitals for managing anesthesia and by pre-hospital emergency medical service
134 providers to reverse opioid overdose. In 1996, fueled by rising fatal heroin overdose among
135 participants and staff, the Chicago Recovery Alliance [24] began distributing naloxone via their
136 syringe services program to people who use drugs and their immediate social networks, an
137 innovation marking the first known formal overdose education and naloxone distribution
138 program in the world [25,26].

139 For the first decade of operations, the naloxone distribution program at Prevention Point
140 Pittsburgh operated within a broader national context, which evolved from an environment of
141 little support to codified scientific and legal protections. Given limited funding during the first 18
142 years (1996 to 2014) of broader intervention evolution, the development and implementation of
143 new naloxone distribution initiatives within syringe services programs nationally was primarily
144 through peer-based mentoring and technical assistance between programs. This was the case
145 with Prevention Point Pittsburgh. Naloxone was purchased using smaller value unrestricted
146 funds from sources such as t-shirt sales and donations to memorial funds from families who had
147 lost a loved one to overdose. The staff time and cost to implement and deliver the services was
148 absorbed by syringe service programs, viewed as an ethical imperative regardless of funding.
149 Using this unfunded interorganizational mentoring model, there were 48 programs in the US by
150 2010 [18], and 140 by 2014 [27]. Because naloxone was a prescription medication, these
151 initiatives existed in a medico-legal gray area that generated onerous requirements on harm
152 reduction programs. For example, from 2005 to 2014, a documented in-person medical
153 encounter and individual prescription from a physician was required for Prevention Point
154 Pittsburgh to dispense naloxone to a participant. After coordinated national advocacy by public
155 health organizations, state level legislation, and accumulating scientific evidence, policies
156 supporting naloxone distribution were established starting around 2014 nationally, and directly
157 contributed to the expansion of the naloxone distribution initiative in Pittsburgh.

158

159 The advent of federal support for naloxone distribution also had an impact on Prevention Point
160 Pittsburgh by creating an expanded community of harm reduction practice for innovation,
161 diffusion, and communication. In 2014, a memo from the Substance Abuse and Mental Health
162 Services Administration (SAMHSA) to the National Association of State and Territorial AIDS
163 Directors (NASTAD) clarified that using federal funds for naloxone was an acceptable
164 expenditure for state block grants [28]. The first new federal funding that explicitly allowed for

165 naloxone distribution was the Health Resources and Services Administration (HRSA) 2015
166 Rural Opioid Overdose Reversal grant program [29]. Prior to federal funding, local governments
167 and harm reduction programs used local and philanthropic funds to support naloxone
168 distribution in Massachusetts [20], New York [14], New Mexico [30], San Francisco [31], Rhode
169 Island [32], North Carolina [21], Baltimore [33], and Pittsburgh [19]. Prevention Point Pittsburgh
170 operated within this community of practice, the activity of which centered around the listserv and
171 monthly meetings of the Opioid Safety and Naloxone Network, facilitated for over a decade by
172 co-author AB [34,35].

173

174 By the end of 2015, several key events paved the way for further development of Prevention
175 Point Pittsburgh's naloxone distribution program. Research emerged confirming that naloxone
176 distribution via syringe services programs was effective at reducing overdose mortality [36] and
177 was cost-effective [37,38]. Laws were passed in 43 states to support expansion [39,40]. Two
178 new branded naloxone products (nasal spray and auto-injector) were approved for prescription
179 use among lay persons [41] and heavily promoted by pharmaceutical manufacturers [42]. Harm
180 reduction programs also created a Buyers Club to obtain low cost injectable naloxone directly
181 from a different manufacturer [34]. The FDA supported development of nonprescription
182 naloxone formulations by conducting studies of labeling instructions [43] and expediting review
183 of new products [44]. Of direct relevance to Prevention Point Pittsburgh, Pennsylvania Act 139
184 was enacted on November 30, 2014, allowing standing orders and third-party naloxone
185 prescriptions. Prevention Point Pittsburgh's Medical Director issued a standing order for the
186 organization, enabling naloxone distribution without requiring individual prescriptions. Other
187 relevant contextual dates are cataloged in Supplemental Material Table S1.

188

189

190 **Research Questions**

191

192 Five research questions were specified in the public pre-registration [45].

193

194 1. Did the utilization rate of naloxone and demographics of participants change after
195 enabling state legislation was enacted?

196

197 2. After enactment of state legislation, what actions did the program take to focus uptake of
198 naloxone directly to networks of people who use drugs?

199

200 3. Were program adaptations (e.g., site expansion) effective in improving naloxone uptake
201 among communities of color in Pittsburgh?

202

203 4. Has the average number of doses of naloxone administered during an overdose
204 response event changed over time as the drug supply has changed? Specifically, was
205 more naloxone needed for reversing overdoses during the era of illicitly manufactured
206 fentanyl, compared to previous periods where overdoses were due to heroin [46]?

207

208 5. Is the number of doses administered per overdose response event impacted by type of
209 naloxone formulation?

210

211 Three additional questions were developed by the co-authors during the iterative analysis
212 process and evaluated in accordance with the Evidence-Making Intervention (EMI) framework
213 (described in Methods).

214

215 6. Did enactment of the Pennsylvania “Good Samaritan” law impact the proportion of
216 overdoses response events in which 911 was called?

217

218 7. What were the circumstances of deaths reported after administration of naloxone?

219

220 8. Did adverse events differ by formulation of naloxone? And did titration of naloxone have
221 an impact on adverse event rates?

222

223 **METHODS**

224

225 **Conceptual Framework**

226

227 This study was based on the EMI framework [17,47]. This framework shifts the locus of
228 evidence production away from universally generalizable knowledge, which is common in
229 traditional biomedical research. Instead, EMI prioritizes a more contextualized scientific process
230 in which data and conclusions are generated through localized public health interventions
231 serving immediate, applied needs. Therefore, the purpose of this analysis is not to present the
232 hypothetically universal experience of naloxone distribution, but rather to examine one location
233 in-depth to understand the forces that directly impacted service delivery and naloxone
234 utilization. The application of the framework to the current investigation can be summarized
235 using the six central tenets of EMI. In applying these principles in the Results section,
236 “Programmatic Context” follows “Quantitative Results” for each set of variables analyzed.

237

- 238 1. *Material-discursive Process*: Naloxone distribution in Pittsburgh is not expected to be
239 the same as anywhere else, yet there is value in understanding the local context.
240 State policies and local drug supply considerations are made when interpreting
241 quantitative data.
- 242 2. *Emergent, Contingent, Multiple effects*: Applied to this study, participant behaviors
243 were expected to change over time. Overdose response practices naturally evolved
244 over a 17-year period, instead of assumed to be static, as in shorter studies.
- 245 3. *Practice-based Matter-of-concern*: Of central relevance is how the concept of
246 naloxone distribution was interpreted by program staff and locally adapted. For
247 example, the program adapted to the COVID pandemic, and as new naloxone
248 products and street drugs shifted. Therefore, contemporaneous contextual details
249 are provided allow quantitative data to be interpreted with fidelity.
- 250 4. *Practice of Implementation*: How the intervention was delivered is of equal
251 importance to other outcomes (e.g., biomedical or pharmacological). Therefore,
252 logistical considerations and site expansion rationales are provided in detail,
253 especially in ways that impacted participant recruitment and training of participants,
254 and ultimately, the quantitative data.
- 255 5. *Performative Work of Science*: Administrative data were collected first and foremost
256 for service delivery, and the scientific knowledge generated from their review is an
257 added benefit. While data were collected with the intention of analysis, the questions
258 asked of participants were also designed to gather information on reversals that
259 would reveal opportunities for counselling and behavior change at the point of care.
- 260 6. *Equality of Knowledge*: Program staff's experience of service delivery is of equal
261 explanatory value as quantification of administrative records. Program staff were
262 included in each step of the analysis process, and their experiences are recorded in
263 the Results section, and they are co-authors of this manuscript.

264

265 The Equality of Knowledge principle, a recursive process for knowledge generation was applied,
266 starting with whole-team generation of the research questions. The data analyst (ND) generated
267 tabular and graphical representations of time trends for batches of variables. The team then
268 assembled to discuss patterns, aberrations, policy impacts, public health implications, and
269 topics for further investigation, including new research questions based on discussions of
270 programmatic context. After the initial discussion, the analyst would prepare follow-up tables,
271 developing statistical methods as the inquiry warranted, and refine time trend graphs, which
272 were then presented at the following meeting. This recursive process was applied to each set of
273 variables in the dataset until all variables had been analyzed and discussed. In addition to the
274 five research questions elaborated in the pre-registration, the recursive process resulted in three
275 additional research questions described above.

276

277 **Data Source**

278

279 We analyzed naloxone dispensing records and participant intake forms from a multi-site
280 comprehensive harm reduction program (e.g., syringe services provider) in Pittsburgh,
281 Pennsylvania, US. Datasets were anonymized by Prevention Point Pittsburgh prior to analysis.
282 Data were generated at either initial training encounters or refill requests by participants, the
283 latter of which included questions about the overdose that the naloxone had been used during.
284 Interviewers received training to ensure standardized data collection, and ongoing data quality
285 assessments were conducted. These administrative records span July 24, 2005 to January 24,
286 2023; initial naloxone distribution started in late July 2005 and the first reversal was reported in
287 August. Data were collected on standardized paper forms, with weekly manual data entry using
288 an electronic record system. Keystroke entry and missing corrections for early years of data

289 were necessary to standardize dates and syntactical conventions (e.g., comma versus semi-
290 colon for list delimiting) using natural language processing (described in Supplemental Material).

291

292 **Naloxone Formulations**

293

294 During the 210-month study period, three formulations of naloxone were predominantly
295 distributed. For both vial sizes of the liquid injectable, following product labelling, participants
296 were instructed that one dose is 1 mL administered intramuscularly. Intramuscular syringes
297 (typically 25 gauge x 1" or 0.5mm x 25 mm) were provided in the kit; intravenous delivery of
298 naloxone was almost never reported. Patient counselling and graphical printed cards advised
299 that intramuscular administration could be achieved directly through clothing, into the shoulder
300 or buttocks. These instructions have long been standardized among harm reduction programs
301 nationwide, with many reproducing the same graphic developed at Chicago Recovery Alliance,
302 and were consistent at Prevention Point Pittsburgh for the entire 17 years. In earlier years, one
303 10 mL vial could have been used in more than one overdose response event; by contrast, even
304 with fractional dosing, 1 mL vials were not reported to be reused. For the nasal spray, one dose
305 was defined as one full actualization in one nostril.

306

307 Naloxone provided in each kit:

- 308 • One 10 mL vial of 0.4 mg/mL naloxone hydrochloride: 2005 to 2015
- 309 • Two 1 mL vials of 0.4 mg/mL naloxone hydrochloride: October 2012 to January 2023
- 310 • Two units of 4 mg naloxone hydrochloride nasal spray: August 2016 to January 2023

311

312 Additional formulations available indirectly or briefly during the study period:

- 313 • 2 mL pre-filled needleless syringes of 1 mg/mL naloxone hydrochloride with aftermarket
314 nasal adaptor [20]. This combination was not distributed by Prevention Point Pittsburgh,
315 but some participants had received it elsewhere and reported using it when presenting
316 for refills.
- 317 • 2 mg naloxone in 400 µL autoinjector. The autoinjector was briefly available in 2016
318 through a small donation of demonstration units from the manufacturer (Kaléo,
319 Richmond, Virginia, US).

320

321 **Definitions**

322

323 *Dose* was defined as the lowest single dose in approved labeling for overdose reversal. For 1
324 mL and 10 mL vials, a single dose was defined as 0.4 mg delivered intramuscularly, and 4 mg
325 intranasally (in one nare) for the nasal spray.

326

327 *Overdose response events* (OREs) include any report of an attempted overdose reversal
328 regardless of the outcome of the event (successful resuscitation, death, or unknown outcome)
329 where naloxone was administered (or in one report attempted to be administered, see Death
330 Case Review). While the term “reversals” is commonly used in the literature, “ORE” was
331 considered a more accurate term in the context of these data.

332

333 *Cumulative utilization rates* are a quantification of how many units of dispensed naloxone were
334 administered to reverse an overdose, during a specified calendar time period. They were
335 calculated in two ways, both with the number of overdose response events as the numerator.

336 The two denominators were either the number of units dispensed or standardized across

337 formulations by the number of doses in a packaged unit. While this provides a useful metric for

338 programmatic and financial planning, and as an input in modeling studies, it only accounts for
339 doses dispensed by and OREs reported to Prevention Point Pittsburgh. Specifically, naloxone
340 obtained via pharmacy or other harm reduction programs would not be accounted for in
341 utilization rate denominators, and OREs not reported to the program would not be accounted for
342 in the numerator.

343
344 “*Felt sick*” was understood by participants and staff to mean “dopesick” from precipitated opioid
345 withdrawal. This is a different semantic meaning than generalized malaise recorded in
346 spontaneous adverse event reporting systems.

347
348 *Titration* in the context of community distribution was the administration of fractional doses of
349 liquid injectable naloxone, as reported by the respondent (e.g., “one and half doses”). Since only
350 the total number of doses were recorded, there may have been instances of titration where two
351 $\frac{1}{2}$ doses were administered but would only appear as a single dose (1.0) in the data. Therefore,
352 this metric should be considered to have high specificity, but with misclassification resulting in
353 bias towards the null in adverse event analyses. Nasal spray and auto-injector formulations
354 were not capable of delivering fractional doses in the manner dispensed.

355

356 **Statistical Analysis**

357

358 In descriptive analyses, *t*-tests were used to assess between-group differences for continuous
359 variables, with the Satterthwaite approximation for degrees of freedom [48] employed when
360 unequal variance between groups was present, or Fisher’s exact test for low cell counts. Two-
361 tailed chi-square distributions were used.

362

363 **Time-series Modeling**

364 Data were aggregated by calendar month. Changes over time were assessed in four ways.
365 First, smoothed monthly time trends (details in Data Visualization) were plotted along with 95%
366 confidence intervals of the mean. Second, to summarize macro time differences between the
367 beginning and end of the observation period, we calculated means within each level of
368 categorical variables which compared the first 24 months to the last six months (Table 2). These
369 timeframes were selected to balance the number of observations, as volume in later years was
370 considerably greater than at the start. Third, record-level data were aggregated by calendar
371 month for segmented regression, specifically piecewise linear regression, to identify abrupt
372 changes in time trends empirically. The model optimized data fitting to a single breakpoint
373 between two straight lines with differing slopes. It was implemented using ‘nl hockey’ in Stata
374 MP version 17 (College Station, TX, USA). Results are summarized in Table 2 and detailed
375 visualizations are in Supplemental Material. Fourth, based on programmatic context and policy
376 implication discussions, further time-trend modeling used linear splines at pre-specified dates if
377 a specific question about an expected changepoint was being evaluated, such as a law enacted
378 on a certain date or a major change in service delivery. Splines were modeled using ‘mkspline’
379 and incorporated as mixed effects linear models using ‘xtmixed’ in Stata.

380

381 **Relative Dose**

382 Relative dose was defined as a relative ratio of the number of doses of naloxone administered
383 in an overdose response event, useful when comparing between formulations. First, average
384 number of doses per ORE were calculated by formulation, reporting the arithmetic mean and
385 95% confidence interval of the mean. Consistently over 17 years, participants had been
386 counselled that 1 mL equals one dose, regardless of whether it came from the 10 mL vial or 1
387 mL vial. Since the 1 mL vial had the lowest number of doses per ORE, it was selected as the

388 reference group. Relative doses by formulation are reported as percent higher doses per ORE,
389 and population averages calculated using scaled Poisson regression, assessed using two-tailed
390 chi-square Wald tests.

391

392 **Rate Differences**

393 To compare adverse event (AE) incidence rates (per 1,000 OREs), rate differences between
394 formulations were also estimated using Poisson regression in Stata, adjusting for the number of
395 doses as a linear continuous variable. Since the 1 mL vial had the lowest rates of adverse
396 events, it was treated as the reference group; the rate difference represents the number of
397 additional adverse events per 1,000 OREs that were observed with the 4 mg nasal spray or
398 multiple formulations, relative to the number of AEs for the 1 mL vial. This metric provides a
399 general measure of population level side effects for each of the major formulations; it is not
400 meant to be interpreted as counterfactual inference as would result from a causal
401 pharmacoepidemiology study where strength of conclusions could be drawn based on control
402 for confounding by formulation.

403

404 **Data Visualization**

405

406 In time series plots, calendar month is presented on the horizontal axis from July 2005 to
407 January 2023 (n=211 months), except for adverse events in Figure 12 which are aggregated by
408 year (2017-22) due to lower incidence and not having been collected in earlier years. The
409 vertical axes are monthly arithmetic means. Overlaid scatterplots represent unadjusted data
410 points. Time series were smoothed with locally estimated scatterplot smoothing (LOESS) and
411 95% confidence interval, with a 6-month window. In Supplemental Material for segmented
412 regression, the two linear segments intervals are visualized instead. Because denominators for

413 time trends can be different across figures, sparklines below the main time trends panel are
414 provided to visualize fluctuations in monthly counts of new participants (Figures 2 and 5),
415 naloxone doses distributed (Figure 6) or administered (Figure 10), or number of ORE (Figure
416 11). For visualizing the number of doses per ORE by formulation in Figure 9, a Gaussian (three
417 sigma) smoother was applied. Figures were generated using Python 3.7 'matplotlib' within a
418 distributed Deepnote (deepnote.com) environment.

419

420 **Death Case Review**

421

422 Prevention Point Pittsburgh conducted a review of reports in which the person administered
423 naloxone was reported to have died. Paper records (encounter notes and written program logs)
424 with interview notes were retrieved for the 23 deaths that were reported by participants who had
425 been at the scene and who had administered naloxone (n=1,909) from 2020 to 2023; only one
426 of these records did not contain any additional contextual information, but circumstances of
427 death were present in the 22 others. Narratives of each death were constructed based on
428 available records and assessed on when naloxone was administered relative to likely time of
429 death, evidence of other causes of death described by health professionals, or other
430 circumstances.

431

432 **Study Conduct**

433

434 **Open Science Practices**

435

436 Pre-registration: DOI [osf.io/b2f4h](https://doi.org/10.1101/2024.11.21.24317731). Codebook, data collection form, and analytic code: DOI
437 [osf.io/sq5d6](https://doi.org/10.1101/2024.11.21.24317731).

438

439 **Institutional Ethics Review**

440

441 This study was reviewed by the University of North Carolina-Chapel Hill Office of Human
442 Research Ethics and deemed to be exempt, as anonymized secondary data research (22-
443 2714).

444

445 **Data Access**

446

447 Data from Prevention Point Pittsburgh were provided to analysts on January 30, 2023. Data
448 were anonymized so no individually identifiable information was available to analysts.

449

450 **Participation of People with Lived Experience**

451

452 People with lived experience of drug use, naloxone distribution, and overdose reversal were
453 involved in the design and conduct of the services provided by Prevention Point Pittsburgh, as
454 well as study conceptualization and interpretation of results. Results were to be reported back to
455 participants of Prevention Point Pittsburgh through posters at program sites, a dedicated
456 website, and a community presentation.

457

458 **Role of the Funder**

459

460 The US Food and Drug Administration is the governmental funder of this manuscript. FDA staff
461 were involved in study conceptualization, data interpretation, and contributed to manuscript
462 development, authorship, and review. The manuscript was reviewed through the FDA clearance
463 process. The contents of this article are solely the responsibility of the authors and do not
464 necessarily represent the official views of the US Food and Drug Administration.

465

466

467 **RESULTS**

468

469 **Overview**

470

471 Descriptive quantitative results and time trend analysis are presented for each variable analyzed
472 first. These are followed by programmatic context notes provided by Prevention Point Pittsburgh
473 staff.

474

475 The first of five topic areas covers characteristics of participants receiving naloxone, which was
476 deemed of high importance by harm reduction program co-authors. The subsequent four
477 sections focus on biomedical and behavioral features: naloxone distribution, circumstances of
478 overdose response events, response behaviors, and adverse events.

479

480 Trends in naloxone distribution and administration were examined from July 24, 2005 through
481 January 24, 2023, comprising an observation period of 211 consecutive calendar months
482 (inclusive), or 17.6 years. A total of 16,904 service encounters by 7,582 unique participants,
483 resulted in 70,234 doses of naloxone dispensed, with 5,521 OREs reported, utilizing 8,756
484 doses of naloxone.

485

486 **New Participant Volume**

487

488 **Quantitative Results**

489 After a decade of steady volume (Figure 1), unique new participant intakes increased sharply
490 starting January 2015. Pennsylvania Act 139 allowed standing orders and third-party naloxone
491 prescriptions, and Prevention Point Pittsburgh's Medical Director issued a standing order for the
492 organization, enabling naloxone distribution without requiring individual prescriptions. Monthly
493 new participant intakes increased from an average of 10.4 per month (95% CI: 9.4, 11.4) to 65.9
494 per month (95% CI: 60.7, 71.1) after the law was enacted, translating to 56.2 (95% CI: 46.5,
495 65.8; Wald χ^2 510, 3 df, $p < 0.001$) additional new participants per month (Figure S1).

496

497 **Figure 1. Monthly volume of new participants trained, naloxone dispensed, and overdose response events**
498 **reported.** Dots are raw monthly counts; lines are moving averages. Three time series are presented on two vertical
499 axes. The left vertical axis is the number of new participants trained and the number of monthly overdose response
500 events reported. The right vertical axis is the monthly count of doses of naloxone dispensed. The vertical red dashed
501 line at December 2014 represents the change in state legislation.

502

503 However, despite the immediate increase in new participants, the utilization of naloxone was
504 lower. Average ORE per new participant enrolled in 2014 was 1.46 (95% CI: 0.84, 2.1), but in
505 2015 after the law change, it fell to 0.47 (95% CI: 0.24, 0.70). This decrease mirrors, in part, a
506 downward secular trend in OREs from 2013-2015 following the emergence of illicitly
507 manufactured fentanyl in 2013, Figure 2. However, though a similar peak in overall OREs
508 occurred in 2016-2017 as carfentanil was known to be circulating, no concurrent spike in new
509 participant OREs occurred after enactment of state legislation. Overall, the trendline in OREs
510 reported by new participants following the law change no longer mirrored the overall trendline, a

511 decoupling that may suggest that new participants tended to be qualitatively different before and
512 after the legislation.

513

514 **Figure 2. Monthly Rates of Overdose Response Events per 100 Doses of Naloxone Dispensed and New**
515 **Participants.** Dots are monthly rates; lines are moving averages. Monthly utilization rates of naloxone during
516 overdose response events (ORE) are presented using doses dispensed and new participants as denominators. Red
517 line at December 2014 represents the enactment of legislation enabling community based naloxone distribution.
518 Study dates: July 2005 to January 2023.

519

520 **Programmatic Context**

521 Program staff verified the quantitative finding that the volume of new participants increased
522 immediately after the law was enacted. However, they also provided context that, compared to
523 previous years, new participants were demographically different: Increases were
524 disproportionately in patients more likely to be older, female and of White race. In early 2015,
525 the venues for overdose prevention trainings shifted from syringe services sites to fire houses
526 and community centers, where audiences were exclusively constituted of the concerned general
527 public, and not people who used drugs themselves. Program staff reported initial excitement at
528 the broader reach of the intervention, but a few months later began to realize that the newly
529 trained general community members were not reporting naloxone utilization or reversals.
530 Accordingly, program staff felt that demographic changes after enactment of the law were
531 crucial to document because they have direct implication on public health practice. Therefore,
532 we proceeded to quantify the programmatic observation that the law led to a change in the
533 underlying population receiving naloxone at Prevention Point Pittsburgh.

534

535 **Participants: Age**

536

537 **Quantitative Results**

538 The median age at the initial training was 40 years (IQR: 31 years, 53 years), Table 1.
 539 Segmented regression (Table 2, Figure S3) identified a breakpoint in April 2015. From 2005 to
 540 2015, average age increased in linear single-year increments during the first decade of
 541 naloxone distribution (Figure 3), so that the average age in 2005 was 31.6 years, and 41.5 in
 542 2015, suggesting a possible birth-cohort influence if the source population is assumed to be
 543 stable without replenishment. Immediately following the enactment of the legislation, new
 544 participants were older: The average age increased from a baseline 37.0 years-old (95% CI:
 545 36.3, 37.7) to 46.0 years-old (95% CI: 45.0, 46.9, *t*-test 14.9, 2048 df, *p*<0.001) the following
 546 year.

Table 1. Participant Characteristics, Behaviors, and Service Utilization

PARTICIPANT CHARACTERISTICS		
Age at Intake		
Arithmetic mean (SD)	42 years (13.6)	
Median (IQR)	40 years (31, 53)	
Missing	119 (1.6%)	
Range	13 to 88 years	
Racial Identity		
	N	%
White	5,362	70.7%
Black	1,533	20.2%
Latinae	96	1.3%
Multi-racial	76	1.0%
Asian-American	26	0.34%
Native American	16	0.21%
Pacific Islander	3	0.04%
Other	46	0.61%
Missing	424	5.6%
Total Participants	7,582	100%
Gender Identity		
Male	3,920	51.7%
Female	3,480	45.9%
Transgender	62	0.82%
Missing	120	1.60%

Total Participants 7,582 100%

NALOXONE DISTRIBUTION

Encounter Type

Initial training	7,567	44.8%
Refill	9,337	55.2%
Total Encounters	16,904	100%

Naloxone Doses Dispensed by Encounter Type

Initial training	27,279	38.8%
Refill	42,955	61.2%
Total Doses	70,234	100%

Reason(s) for Refill (multiple choice)

Used it	5,521	57.5%
Need extra kit	2,307	24.0%
Gave it away	1,009	10.5%
Expired	375	3.9%
Lost	264	2.7%
Taken by law enforcement	37	0.4%
Other	89	0.9%
Total Refill Reasons	9,602	100%

OVERDOSE RESPONSE EVENTS REPORTED

Who Administered Naloxone

Person prescribed naloxone	4,374	79.2%
Someone else (bystander)	1,077	19.5%
Missing	70	1.3%
Total Reversals	5,521	100%

Naloxone Used On

Friend	4,483	81.2%
You (person reporting)	491	8.89%
Family member	268	4.85%
Stranger	240	4.35%
Missing	39	0.71%
Total Reversals	5,521	100%

Doses Administered per ORE

Arithmetic mean (SD)	1.63 doses (0.99)
Median (IQR)	1 dose (1, 2)
Missing	133 (2.4%)
Range	0.25 to 10 doses

RESPONSE BEHAVIORS & SERVICE UTILIZATION

Rescue Breathing

No	2,768	50.1%
Yes	2,419	43.8%
Missing	334	6.0%
	0	0%
Total Reversals	5,521	100%

Chest Compressions*

No	2,092	69.60%
Yes	711	23.70%
Missing	201	6.70%
Total Reversals	3,004	

Called 911

No	4,530	82.0%
Yes	903	16.4%
Missing	88	1.6%
Total Reversals	5,521	100%

**Ambulance Arrived After Calling
911**

No	456	50.5%
Yes	444	49.2%
Missing	3	0.33%
Total 911 Calls	903	100%

Hospital Transport

No	5,209	94.3%
Yes	274	4.96%
Missing	38	0.69%
Total Reversals	5,521	100%

*Collected November 2015 to December 2020

547

548

Table 2. Participant characteristics, behaviors, and adverse reactions in first 24 month and last 6 months, with segmented regression breakpoints

	First 24 months		Last 6 months		Segmented Regression				
	Mean	95% CI	Mean	95% CI	Break Month	95% CI	Test	Slope Before	Slope After
Participants									
<i>Participant volume per month</i>									
Average Age of Participants	31.6 years	27.7, 35.5	41.5 years	39.9, 43.1	Apr 2015	Oct 2008, Feb 2017	10.8, 3 df, p<0.001	0.11	-0.01
Percent Female	34.9%	24.9%, 45.0%	48.3%	39.3%, 57.3%	<i>None found</i>
Percent Non-White	11.3%	6.0%, 16.6%	29.8%	19.4%, 40.2%	Jan 2015	May 2012, Oct 2017	7.0, 3 df, p<0.001	0.07	0.29
Percent Black race	4.9%	1.5%, 8.3%	24.0%	16.2%, 31.7%	Dec 2015	Feb 2014, Nov 2017	63.9, 3 df, p<0.001	0.05	0.31
Refill Reason									
<i>Percent of refills dispensed</i>									
Expired	1.4%	0%, 4.3%	0.80%	0.30%, 1.3%	April 2010	Jul 2009, Jan 2011	12.7, 3 df, p<0.001	0.39	-0.13
Used It	71.1%	54.0%, 88.2%	27.8%	24.0%, 31.6%	Aug 2017	Jul 2016, Sep 2018	22.5, 3 df, p<0.001	0.01	-0.91
Gave Away	0%	.	20.5%	15.8%, 25.3%	Jul 2018	Jan 2018, Dec 2018	58.1, 3 df, p<0.001	0.004	0.35
Need Extra	0%	.	23.3%	19.2%, 27.1%	Jan 2012	Aug 2010, Jul 2013	8.8, 3 df, p<0.001	0.015	0.21
Taken By Police	2.7%	0%, 5.9%	0.7%	0%, 25%	Jun 2009	.	0.32, 3 df, p=0.75	.	.
Naloxone Used on Whom									
<i>Percent of reversals reported</i>									
Friend	74.8%	62.0%, 87.6%	72.4%	58.6%, 86.1%	Jun 2013	Aug 2011, May 2015	8.3, 3 df, p<0.001	0.21	-0.15
You (person reporting)	7.6%	1.6%, 13.6%	16.3%	8.8%, 23.8%	May 2018	Dec 2016, Oct 2019	17.5, 3 df, p<0.001	-0.04	0.32
Family member	1.4%	0%, 4.3%	2.8%	0%, 6.0%	Jul 2018	Nov 2014, Feb 2022	7.0, 3 df, <0.001	0.02	-0.06
Stranger	0.95%	0%, 2.5%	7.9%	0.5%, 15.2%	<i>None found</i>
Response Behaviors & Services									
<i>Percent of reversals reported</i>									
Rescue Breathing	52.1%	35.5%, 68.7%	34.3%	23.2%, 45.3%	Jan 2014	Oct 2009, Apr 2018	4.0, 3 df, p<0.001	0.013	-0.24
CPR Performed (percent of reversals)	35.80%	22.0%, 29.6%	9.0%	6.1%, 11.9%	Aug 2017	Feb 2016, Feb 2019	15.6, 3 df, p<0.001	0.31	-0.25
911 Called (percent of reversals)	6.9%	2.4%, 11.5%	5.4%	4.6%, 6.3%	Dec 2017	Apr 2016, Aug 2019	9.6, 3 df, p<0.001	0.06	-0.16
Hospital Transport*	0%	.	7.7%	3.3%, 12.0%	<i>None found</i>
Doses Per ORE	1.30 doses	1.04, 1.55	1.78 doses	1.65, 1.92	<i>None found</i>		0.28, 3 df, p=0.60		

Adverse Reactions

"Felt sick"	3.9%	1.7%, 6.0%	1.5%	0%, 3.4% 4.4%	Aug 2019	Apr 2019, Jan 2020	43, 3 df, p<0.001	0.006	-0.007
Angry	3.1%	1.2%, 4.9%	11.9%	19.4%	May 2020	Sep 2019, Dec 2020	35, 3 df, p<0.001	0.004	-0.003
Shaking	2.2%	0.9%, 3.5%	0%	.	Dec 2018	Sep 2016, Mar 2021	5.7, 3 df, p=0.0013	-0.0006	-0.0003
Confused	0.10%	0%, 0.3% 0.03%	0.64%	0%, 1.7% 12.3%	<i>None found</i>		0.18, 3 df, p=0.18		
Emesis	0.05%	0.08%	22.5%	32.8%	<i>None found</i>				
Diarrhea	0.09%	0%, 0.3%	0.28%	0%, 0.99%	<i>None found</i>				

* Zero and low sample size values in first months may cause unstable arithmetic means. See supplemental material for plots.

550 **Figure 3. Average age of new participants receiving overdose reversal training and naloxone.** Dots represent
551 average age of new participants, by month. Time series of monthly average age for new participants receiving initial
552 overdose prevention training and naloxone dispensing. Time series line (orange) and shaded 95% confidence interval
553 of the mean (light blue) have been smoothed, and raw average age per month is depicted as dots. Inset plot is a
554 histogram of average age of new participants, by 5-year bin increment, during the entire observation period: July
555 2005 to January 2023.

556

557 **Programmatic Context**

558 Program staff observations corroborated quantitative findings. The immediate increase in age
559 during 2015 was due to large-audience naloxone training events hosted by Prevention Point
560 Pittsburgh that attracted parents concerned about their children. These events were often held
561 in venues outside of Pittsburgh city limits [49], including suburban and rural areas of western
562 Pennsylvania. In a departure from traditional service delivery, these large-audience events
563 attracted more family and friends than people who use drugs.

564

565 This increase in terms of age leveled out by the end of 2016 as Prevention Point Pittsburgh
566 refocused outreach efforts to serve people who use drugs instead of concerned friends and
567 family. This change in focus was made intentionally by program staff in early 2016 because
568 there were fewer-than-expected ORE reports despite the large increase in new participants.
569 Program staff believed that naloxone distributed in the mass training events to friends and
570 family were less likely to be used, compared to when distributed directly to people who use
571 drugs. In the most recent data years (2022-3), the downward age trend was explained as being
572 due to programmatic expansion to mobile sites in previously underserved neighborhoods
573 drawing younger populations.

574

575 **Participants: Gender Identity**

576

577 **Quantitative Results**

578 Self-reported gender identity was 51.7% male, 45.9% female, and 0.82% (n=62) transgender
579 during the entire observation period. Although segmented regression did not identify a single
580 breakpoint, visual inspection of the timeline (Figure 4) and discussion with Prevention Point
581 Pittsburgh staff suggested that the percent of new participants identifying as female increased in
582 2015-16, immediately following the enactment of the aforementioned naloxone law. The percent
583 of female new participants increased from 34.6% (95% CI: 31.4%, 37.8%) to 58.1% (52.7%,
584 63.5%, *t*-test 8.0, 22 Satterthwaite df, *p*<0.001) in the calendar year before and after legislation.

585

586 **Figure 4. New participant volume and self-reported gender for naloxone training and dispensing.** Top frame
587 depicts timeline in new participant volume receiving naloxone at initial training encounters, by self-reported gender.
588 River plots are interpreted as stacked area graphs, with area above and below zero both being in the “positive”
589 direction by category. The vertical red dashed line at December 2014-to-January 2015 interface represents the
590 change in state legislation. Bottom frame is a smoothed sparkline of total volume of all new monthly participants.
591 Study dates: July 2005 to January 2023.

592

593 **Programmatic Context**

594 Quantification confirms observations by Prevention Point Pittsburgh staff that after the
595 legislation there was increased representation of concerned females (often mothers of children
596 who use opioids) who attended large training events. After 2016, Prevention Point Pittsburgh
597 made the conscious decision to re-prioritize people who are actively using drugs for naloxone
598 outreach, and the percent female new participants stabilized to around 40-50% per month. In
599 recent years (2022-23), there was a noticeable uptick in the proportion of females to 50-60%,
600 concurrent with the younger average age noted previously. This period is contemporaneous

601 with a shift to nasal naloxone formulations distributed and expansion of mobile sites to new
602 Pittsburgh neighborhoods, with the caveat that this association may be incidental.

603

604 **Participants: Racialized Identity**

605

606 **Quantitative Results**

607 Self-reported racialized identity of participants was 70.7% White, 20.2% Black, 1.3% Latine, 1%
608 multiracial, with less than 1% each of others, Table 1. The racial distribution mirrored the
609 population of Allegheny County, with greater representation by individuals identifying as Black,
610 and fewer of Latine origin [50]. Unlike age and gender, the impact of the state legislation on race
611 was less immediately evident and more nuanced. Segmented regression identified an inflection
612 point in January 2015, showing an increase in non-White new participants (Table 2, Figure S4).
613 However, segmented regression revealed that the increase in Black new participants did not
614 actually start until a year later, after the end of December 2015 (Table 2, Figure 5).

615

616 **Figure 5. Racial identity of new participants dispensed naloxone.** Top frame depicts timeline in new participant
617 volume to naloxone training and dispensing, by self-reported racial identity. The vertical red dashed line at December
618 2014 represents the change in state legislation. Bottom frame is a smoothed sparkline of total volume of all new
619 monthly participants. Study dates: July 2005 to January 2023.

620

621 **Programmatic Context**

622 Prevention Point Pittsburgh staff noted that the increase in Black participants after 2015 was not
623 surprising and was planned. A retrospective analysis of the first ten years of service delivery was
624 conducted by staff in 2016 [16], which starkly quantified what up until then had been a casual

625 observation, namely that the predominant race of participants was White, and that different
626 strategies would be needed to engage people of color.

627

628 The statistical breakpoint in January 2016 conforms with a significant service change: In
629 February 2016, Prevention Point Pittsburgh intentionally increased outreach to a predominantly
630 Black neighborhood via mobile-based services and hiring community health advocates from the
631 community to do naloxone distribution. A second predominantly Black neighborhood was served
632 starting in late September 2019. While the law itself did not lead to a passive increase in Black
633 participants, Prevention Point Pittsburgh staff did credit the law in allowing them to distribute
634 naloxone in more places. For example, a barber shop in a predominantly Black neighborhood
635 served as an early expansion site for naloxone distribution, a partnership that was brokered with
636 the support of a local community leader identified by program staff. Staff further noted this active
637 outreach was different than inbound solicitations from community groups for naloxone trainings;
638 people who sought out Prevention Point Pittsburgh for group trainings tended to be serving
639 White communities.

640

641 **Iterative Modeling and Further Contextualization**

642 Based on explanations by Program staff, time trend analysis was refined. Spline models with
643 knots at the dates of law enactment and the two outreach expansion dates demonstrated good
644 fit for these inflection points; however, the period from September 2019 to January 2023
645 displayed non-linear temporal distribution (Figure S5). Visual inspection was corroborated
646 empirically by the predicted output from the mixed effects model, which showed that the percent
647 of Black new participants increased considerably after September 2019 ($\hat{y}_{\text{September}} = 27.0\%$ to
648 $\hat{y}_{\text{October}} = 39.2\%$).

649

650 However, time-restricted segmented regression (Figure S4) identified a potential change point
651 of December 2020 after which a decline in the percent of Black participants accelerated through
652 the end of observation in January 2023, a result of expanded mobile services in another
653 Pittsburgh neighborhood with a younger, predominantly White population. This particular mobile
654 site was characterized by physicians who could start low-threshold buprenorphine inductions
655 (i.e., a flexible treatment approach with same-day initiation, relaxed adherence requirements,
656 and availability in non-traditional settings) [51] in the field. Low-threshold buprenorphine
657 provision also drew participants to the harm reduction service side of the program, where take-
658 home naloxone was also provided. Therefore, the increase in younger, White participants was
659 the combined function of local demographics and the spillover effect stemming from providing
660 medications for opioid use disorder.

661
662 In summary, enactment of a law in Pennsylvania led to an immediate increase in naloxone
663 dispensed to concerned family and friends of people who use drugs. The law enabled
664 Prevention Point Pittsburgh to expand to underserved neighborhoods, but inclusion of more
665 racialized minorities also required service delivery innovation.

666

667 **Naloxone Distribution**

668

669 **Quantitative Results**

670 During the 17-year period, half of all naloxone doses dispensed by Prevention Point Pittsburgh
671 were in 1 mL (0.4 mg/mL) vials (n=35,715; 50.8%), followed by 10 mL (0.4 mg/mL) vials
672 (n=18,420; 26.2%), and 4 mg nasal spray (n=16,063; 22.9%). Only 36 doses of the autoinjector
673 were dispensed during a one-month period in 2016 with donated product. During the first

674 decade of operation (Figure 6), Prevention Point Pittsburgh distributed the 10 mL vial
675 exclusively.

676

677 **Figure 6. Major forms of naloxone distributed, July 2005 to January 2023.** In the top panel, smoothed time series
678 are displayed along with 95% confidence intervals of doses dispensed per month, by formulation. Colored dots
679 represent raw counts of doses by month. The bottom panel is a sparkline showing total number of doses per month of
680 naloxone distributed across all formulations. Initially only 10 mL vials were available for distribution. The vertical red
681 dashed line at December 2014 represents the change in state legislation. The only other form of naloxone distributed
682 by Prevention Point Pittsburgh was 36 units of an auto-injector in June 2016, which are not depicted. Study dates:
683 July 2005 to January 2023.

684

685 **Programmatic Context**

686 Program staff provided context for the two points where lines crossed. Initially the 10 mL vial
687 was the only formulation available, but the 10 mL vial was replaced by 1 mL vials starting in
688 October 2012 due to a new contract with the manufacturer. With this transition, by August 2013
689 all IM distribution was of 1 mL vials, packaged by the program as kits containing two 1 mL vials.
690 The other line crossing occurred in Spring 2021 when a manufacturing problem disrupted 1 mL
691 vial production. From May 2021 to September 2022, a manufacturing shortage of affordable
692 naloxone led to a shortage of the 1 mL vials. The State of Pennsylvania was able to increase
693 bulk nasal naloxone to Prevention Point, but the organization had to hire a part-time staff person
694 to help other community-based programs with accessing the state ordering portal. After the
695 shortage was resolved, 1 mL vial purchases resumed in late 2022.

696

697 **Reasons for Refill**

698

699 **Quantitative Results**

700 Over the 17.6 years, there were 16,904 participant-encounters by Prevention Point Pittsburgh
701 staff, of which 44.8% (n=7,567) were initial trainings (Table 1). The remainder of dispensing
702 events occurred when refill requests participants who had previously been trained returned for a
703 refill.

704

705 A total of 70,234 doses of naloxone were dispensed: 27,279 during initial training encounters
706 (38.8%) and 42,955 (61.2%) during refills. The average number of doses dispensed per
707 participant was 4.15, cumulatively.

708

709 “Used it” was the most common reason for refill in 57.5% of refill requests (Table 1, Figure 7).
710 Segmented regression revealed that prior to August 2017, about 70% of refill requests were
711 after naloxone had been used (Table 2, Figure S8). After this date, participants increasingly
712 asked for refills for other reasons.

713

714 **Figure 7. Reasons for requesting naloxone refills.** Smoothed sparklines depicting monthly proportion of refill
715 requests by reason for refill. Grey dots represent raw counts by month, while the colored lines are smoothed monthly
716 average. Study dates: July 2005 to January 2023.

717

718 Obtaining a refill for naloxone because of expiration date was relatively rare, at 3.9% of refill
719 requests overall. Segmented regression found an initial decrease in expired naloxone after April
720 2010 (Table 2), but inspection of trendlines (Figure 7) reveal further peaks over time, finally
721 stabilizing in a lower proportion of refills from 2017 or 2018 onwards. Comparing these findings
722 to Figure 6, the likelihood of expired naloxone refill does not correspond to the switch from 10
723 mL vials to 1 mL vials in calendar years 2012 to 2013. The further decline in proportion of
724 expired naloxone in later years (2017 onwards) is somewhat contemporaneous with availability
725 of the nasal spray, but samples are too small to draw further conclusions.

726

727 “Need an extra kit” was used by program staff to record when individuals who already had a kit
728 and wanted a second one. This comprised 24.0% of refill requests overall, and segmented
729 regression identified January 2012 as a change point (Table 2, Figure S7). Cumulatively, about
730 30% of refill requests were for this reason. This does not include people who used a kit and
731 were looking for a refill.

732

733 “Gave away” increased substantially starting around July 2018 (Table 2, Figure S6), as
734 suggested by segmented regression. While this reason was only 10.5% cumulatively, nearly a
735 quarter of all refill requests were because of secondary distribution (“gave away”). Secondary
736 distribution is a well-documented phenomenon where participants directly accessing harm
737 reduction services obtain additional supplies for distribution among their peer networks
738 informally [52,53].

739

740 Law enforcement confiscation of naloxone occurred mostly before the enactment of the
741 statewide standing order in December 2014, in 37 instances. Other reasons for refill were very
742 rarely reported (less than 1% combined), including only one or two reports of breakage of glass
743 vials.

744

745 **Programmatic Context**

746 Program staff clarified that, following the law change, increased participant reports of sharing
747 naloxone with others (“gave away”) may not represent a true change in behavior, but rather a
748 gradual increase in participants’ level of comfort reporting giving away naloxone as a form of
749 secondary distribution, a phenomenon documented elsewhere after law changes [54]. Prior to
750 the law change and the official sanction of naloxone distribution, coded language was often

751 used by participants to emphasize the *personal* need for the naloxone because third-party
752 prescribing was not legally sanctioned. Program staff attributed the legacy of prescription status
753 and the requirement to have a documented clinical encounter as having conditioned participants
754 to only talk about needing naloxone for themselves. As third-party prescribing of naloxone
755 became less legally risky over time, participants became more willing to candidly discuss that
756 they were giving their naloxone kits away to others. Prevention Point Pittsburgh staff noted a de-
757 stigmatizing of naloxone after the passage of the law, an advance that was critical to enabling
758 more honest dialogue with participants about their experiences.

759

760 Program staff provided more context for “need an extra kit” responses. This category often
761 refers to individuals wanting to have naloxone available in multiple locations, such as both at
762 home and in cars, or one for home and one to carry in a handbag.

763

764 **Naloxone Administration**

765

766 Naloxone administration reports were limited to those instances where naloxone had been used
767 (n=5,521), instead of refill requests for other reasons. Naloxone was generally *administered* by
768 the person to whom it had been prescribed and trained in 79.2% (n=4,374) of OREs, leaving
769 19.5% on average administered by “someone else” at the scene (Table 1). However, this was
770 different (Wald $\chi^2=218$, df 5, $p<0.001$) by formulation: 33.2% of OREs with nasal sprays were
771 done by someone else, whereas intramuscular formulations ranged from 10.1% to 16.4%. This
772 suggested the necessity to examine to whom the naloxone was administered.

773

774 **Naloxone Used on Whom**

775

776 **Quantitative Results**

777 The largest category represents 81.2% of ORE that were performed on friends and
778 acquaintances, which decreased slightly over time (Figure 8, Table 1). Segmented regression
779 yielded June 2013 as a change point after which other categories of people slightly increased in
780 being administered naloxone instead of friends and acquaintances (Figure S10).

781

782 **Figure 8. Person to whom naloxone was administered, monthly proportion of ORE reports.** Dots represent
783 monthly proportions for each exclusive category. Percents are based on total ORE reports as the denominator. The
784 majority of naloxone administrations were performed on friends or acquaintances of the person reporting the
785 overdose response event. “You” refers to the overdose having been experienced by the person who was reporting
786 the overdose. Study dates: August 2005 to January 2023.

787

788 Naloxone was used on the person reporting the ORE (“you”) in only 8.9% of cases. In these
789 cases, the person who had been prescribed naloxone was also the person who had
790 experienced the overdose and was self-reporting the ORE. Self-reported OREs were 7.6% in
791 the first two years of program operations and had continued to decline until May 2018 after
792 which they approximately doubled (Table 2, Figure S9). In the last 6 months of the observation
793 period, the person reporting the ORE was also the person who experienced the overdose in
794 16.3% of reports. Interestingly, the percent of OREs on the reporter themselves was twice as
795 high for nasal sprays (16.9%) than for injectable (8.5% 10 mL vial, 5.9% 1 mL vial) formulations.

796

797 Naloxone was administered on family and strangers rarely. OREs on family members were
798 4.8% overall (Table 1, Figure S11). In segmented regression, family OREs climbed gradually,
799 but July 2018 emerged as a possible change point after which OREs of family members
800 declined. Use on family members did not differ by formulation type (range across formulations:

801 4.4% to 5.3%), suggesting that both intramuscular and nasal formulations were equally likely to
802 be used on family.

803
804 During the first two years of operations, naloxone administration to strangers was less than 1%
805 but increased to 7.9% of ORE reports in the last 6 months of observation. Cumulatively, there
806 were 239 (4.4%) total OREs on strangers. No change point was detected in segmented
807 regression models. The nasal spray was slightly more likely to be used on strangers (5.7%,
808 n=78) than the 1 mL vial (4.2%, n=128), and ahead of the 10 mL vial (2.7%, n=23) distributed in
809 early years.

810

811 **Programmatic Context**

812 Prevention Point Pittsburgh staff offered a plausible explanation for the increase in “you” as the
813 person who had been revived from overdose with naloxone. In the latter two years of the
814 observation period, a community outreach worker had been specifically engaging with “trap
815 houses” where people congregated to use drugs [55,56]. Naloxone distribution in trap houses
816 followed a different pattern than other types of community distribution, in what amounted to
817 active case finding of people who had already experienced an overdose. The outreach worker
818 would bring naloxone for distribution to the trap house, ask if anyone had recently had an
819 overdose reversed with naloxone, and record these reversals. This practice was important for
820 targeting naloxone distribution to a population who had already experienced an overdose and
821 remained at elevated risk for subsequent overdoses. The corresponding data implication was
822 that trap house delivery resulted in more “you” reports because naloxone was being provided to
823 people *after* experiencing an overdose that had been reversed with naloxone by a peer. This
824 stands in contrast to other community outreach settings where naloxone was provided to people
825 *before* they had experienced an overdose.

826

827 Program staff did not have specific contextual or programmatic explanation for the increase in
828 administration on strangers, pointing to the small numbers and cautioning against drawing
829 conclusions. Staff emphasized that people use whichever formulation they have on hand, and
830 that differences in rates usage by formulation are not purely a function of device usability. At
831 Prevention Point Pittsburgh, where both intramuscular and nasal naloxone are equally available
832 and participants are given the choice of which naloxone to take with them, many participants
833 select intramuscular formulations if they believe *themselves* to be at risk of an overdose, and
834 conversely, choose the nasal formulation if they expect to administer it *on acquaintances*.
835 Therefore, when a stranger is encountered in an unresponsive state, participants administer
836 whichever formulation of naloxone they are carrying at the time. Staff emphasized the parity
837 between injectable and nasal formulations, in terms of usability and preference, as reported by
838 the participants; each has its place in community-based overdose response and there was no
839 strong preference for the nasal spray just based on its form factor.

840

841 **Naloxone Doses Administered**

842

843 **Quantitative Results**

844 The cumulative number of naloxone doses administered was 8,756, leading to 5,521 ORE
845 reports, Table 3. The frequency of administered dosage forms was: 52% as 1 mL vials
846 (n=4,551.25 doses), 25.3% as 4 mg nasal sprays (n=2,216 doses), and 18% as 10 mL vials
847 (n=1,555.25 doses). Multiple forms of naloxone were administered in 151 ORE reports (4.7%,
848 n=408.5 doses, Table 3).

849

850

Table 3. Distribution, overdose responses, and dosing by naloxone formulation

NALOXONE DISTRIBUTION

Naloxone Formulation	Dispensed by Prevention Point	
	Units	Doses
1 mL vial	35,715 vials	35,715
Nasal spray (4 mg)	8,032 two-packs	16,063
10 mL vial	1,842 vials	18,420
Autoinjector	18 two-packs	36
Nasal adaptor		0
Multiple forms		.
Missing		0
Totals		70,234

OVERDOSE RESPONSE EVENTS

	Reversals	%	Utilization: ORE per Unit or Dose	
			By Units	By Dose
1 mL vial	3,082	56	8.6%	8.63%
Nasal spray (4 mg)	1,373	25	17.1%	8.55%
10 mL vial	880	16	47.8%	4.78%
Autoinjector	14	0	77.8%	38.9%
Nasal adaptor	1	0		
Multiple forms	151	3		
Missing	20	0		
Totals	5,521	100		

DOSES ADMINISTERED

	Doses per ORE					
	Doses	Mean	95% CI	Relative Dose	95% CI	Wald Test
1 mL vial	4,551.25	1.51	1.48, 1.54	ref		
Nasal spray (4 mg)	2,216	1.63	1.58, 1.68	+7.5%	3.7%, 11.5%	x2=3.9; p<0.001
10 mL vial	1,555.25	1.85	1.75, 1.94	+22.1%	15.6%, 28.9%	x2=7.1; p<0.001
Autoinjector	23	1.64	1.20, 2.08	+8.6%	-16.2%, 40.7%	x2=0.6; p=0.53
Nasal adaptor	2	2.00		+32.2%	29.7%, 34.7%	x2=28.8; p<0.001
Multiple forms	408.5	2.76	2.58, 2.94	+82.4%	70.3%, 95.4%	x2=17.1; p<0.001
Missing	153					
Totals	8,756					

Poisson regression, with x2-scaled residuals, and robust variance estimator, using complete case data (n=5,375). 1 mL vials used as referent group.

Model-based Wald x2 test, df 4

* Estimated under the assumption that doses administered were dispensed by Prevention Point Pittsburgh. As the presence of the nasal adaptor report suggests, some participants may have obtained naloxone from other sources, such as pharmacy or other harm reduction programs, and would not be accounted for in the denominator.

852

853 Cumulative utilization rates are a quantification of the number of dispensed doses used in
854 OREs. Dose-standardized utilization rates were similar for the 1 mL vial (8.6%) and nasal spray
855 (8.5%), and 4.8% for the 10 mL vial (Table 3).

856

857 The cumulative arithmetic average number of naloxone doses per overdose response event
858 was 1.63 (95% CI: 1.60, 1.65), and the geometric mean was 1.44 (95% CI: 1.42, 1.46). Time
859 trends presented in Figure 9 show two distinct patterns. The 1 mL vial and 4 mg nasal spray
860 were used mostly as one or two doses (roughly bimodal), whereas the 10 mL vial and multiple
861 forms represent more continuous distributions, including titrated fractional doses and
862 administration of less than one full labeled dose to achieve reversal. When multiple forms of
863 naloxone were administered, the number of total doses was greater (median of two versus
864 median of one) than single formulation administrations.

865

866 **Figure 9. Number of naloxone doses administered per overdose response event.** Average number of naloxone
867 doses administered per overdose response event are presented with the vertical axis, smoothed using Gaussian
868 kernel density estimators. For 1 mL and 10 mL vials, fractional dosing was observed, with less than a single full dose
869 (1 mL of 0.4 mg/mL) being administered; this was not possible for the nasal spray, resulting in the visible left-
870 truncation of the kernel density plot. Box plots below each graph show median and interquartile range are presented
871 horizontally; circles represent outlier observations. Study dates: August 2005 to January 2023.

872

873 The average doses per overdose response event was lowest for 1 mL vial with 1.51 doses (95%
874 CI: 1.48, 1.54), Table 3. Using 1 mL vials as a reference group, the average number of doses
875 per ORE was 7.5% higher (95% CI: 3.7%, 11.5% higher, $\chi^2=3.9$, Wald $p<0.001$) for the nasal
876 spray with 1.63 doses per ORE (95% CI: 1.58, 1.68). For the 10 mL vial, doses were 22.1%
877 (95% CI: 15.6%, 28.9% higher doses, $\chi^2=7.1$, $p<0.001$) higher than the 1 mL vial with 1.85

878 doses per ORE (95% CI: 1.75, 1.94). When multiple forms were used, the average doses were
879 2.76 doses per ORE (95% CI: 2.58, 2.94).

880
881 The overall rate of naloxone doses per overdose response event in Pittsburgh remained stable
882 over a 17-year period (Figure 10). Segmented regression did not yield any statistically verifiable
883 change points ($\chi^2= 0.28$, 3 df, $p=0.60$; Table 2) during the 17-year observation period of the
884 number of doses per overdose response event (Figure S13).

885
886 **Figure 10. Time trends in naloxone doses per overdose response event, cumulatively and by**
887 **formulation.** Average number of naloxone doses administered per overdose response event for all formulations are
888 presented in the top frame. In the bottom frame the same data are broken out by the three dominant formulations.
889 The vertical axis corresponds to average monthly dose per overdose response event, with dots representing the raw
890 monthly average, and the trend lines depicting the Gaussian-smoothed rolling three-month rolling average. Shaded
891 fill areas represent the 95% confidence interval of the smoothed mean doses per overdose response event per
892 month. Study dates: July 2005 to January 2023.

893

894 **Programmatic Context**

895 Program staff described that with the 10 mL vial it was easy for people to administer additional
896 doses, and that unit dosing with the 1 mL vial and nasal spray reduced this behavior. In
897 instances where many doses and/or multiple forms had been administered, program staff
898 described that it was common for people to receive additional doses of naloxone after police or
899 paramedics arrived, even if the person was already revived and was breathing. Therefore,
900 extreme numbers of reported doses administered may reflect circumstances beyond the
901 reporter's control, and doses not dispensed by Prevention Point Pittsburgh. Dose titration was
902 also identified by program staff and the rest of the study team as an important phenomenon for
903 exploration, and one that had not been previously characterized in scientific publications.

904 Program staff believed that titration would be associated with fewer or less severe withdrawal-
905 related adverse events, and this hypothesis was the basis for subsequent investigation.

906

907 **Response Behavior: Rescue Breathing**

908

909 **Quantitative Results**

910 The percent of overdose response events in which rescue breathing was reported was 43.8%
911 (n=2,419 out of 5,521), Table 1. Segmented regression identified January 2014 (Figure 11) as a
912 possible changepoint after which the percent of ORE with rescue breathing declined (Figure
913 S14). In the last 6 months of observation, 34% of overdose response events mentioned rescue
914 breathing, down from 52% in the first 2 years of the observation period (Figure 11). The COVID-
915 19 pandemic did not appreciably accelerate the long-term temporal trend of declining rescue
916 breathing during overdose response events. Segmented regression with an imposed breakpoint
917 in March 2020 did not produce a meaningful statistical association, meaning that rescue
918 breathing continued to decline at a linear decay trajectory consistent with the immediately
919 preceding time period (Figure S14), independent of the pandemic.

920

921 **Figure 11. Proportion of naloxone administration reports in which response behaviors were**
922 **reported.** Smoothed time series depicting the percent of overdose response events in which response behaviors
923 were reported. The bottom panel shows monthly volume of total overdose response events (ORE). Study dates:
924 August 2005 to January 2023.

925

926 **Programmatic Context**

927 During the study period, Prevention Point Pittsburgh trainings recommended rescue breathing
928 during an overdose response event. However, this recommendation was not made strongly

929 during the height of the COVID-19 pandemic, but was re-emphasized in trainings starting in
930 2023, after xylazine started appearing in the local unregulated opioid supply in 2022 [57].
931
932 Program staff also noted that while rescue breathing was taught at the initial trainings, it was not
933 reinforced during refill encounters, with one exception: If participants reported needing to use
934 more than 2 doses of naloxone, they were counselled to use rescue breathing and count
935 respiration in future reversals. Therefore, the slight uptick in rescue breathing in 2022 may have
936 been influenced by this directive. In the same year, xylazine started to appear alongside
937 fentanyl in the local unregulated drug supply, complicating reversals because the person who
938 had overdosed may not become responsive to stimuli upon naloxone administration, even if
939 respiration was adequately restored. It was not until March 2023, beyond the end of
940 observation, that Prevention Point Pittsburgh formalized the recommendation to reemphasize
941 counting breaths after naloxone administration (and provide rescue breathing if needed) to
942 participants via handouts and flyers in the context of xylazine; the intent was to dissuade
943 unnecessarily high doses of naloxone being administered if the participant was breathing
944 adequately but did not become immediately reanimated. This was also contemporaneous with
945 the start of disposable xylazine test strip distribution. While this programmatic evolution was not
946 formalized until after the end of the observation period, Prevention Point Pittsburgh noted that
947 the same advice had been delivered to participants in less systematic ways in the months prior.
948 Staff also pointed out that the current over-the-counter label [43] for naloxone nasal sprays does
949 not include instructions for rescue breathing but that they provide the instructions themselves.

950

951 **Response Behavior: Chest Compressions**

952

953 **Quantitative Results**

954 Data on chest compressions (commonly called “CPR” for cardio-pulmonary resuscitation) were
955 recorded from 2016 to 2023. Chest compressions were reported to have been conducted in only
956 23.7% of OREs (n=711 out of 3,004 reports). Segmented regression identified February 2017
957 as a changepoint after which chest compressions declined (Table 2, Figure 11)

958

959 **Programmatic Context**

960 Prevention Point Pittsburgh staff pointed out that in 2016, the New York State Health
961 Department convened a working group of physicians and scientists to establish the necessity of
962 recommending CPR for opioid overdose reversal. At the time, CPR was recommended widely in
963 Canada but not by the World Health Organization, and within the US instructions were
964 inconsistent. The onset of data collection at Prevention Point was intended to inform this
965 debate. The medical consensus of the New York State working group was that chest
966 compressions were not required [58]. As a result, Prevention Point Pittsburgh modified
967 recommendations to participants de-emphasizing chest compressions, which had been part of
968 the original training. They attribute the decline in CPR in 2017 to be related to this programmatic
969 shift.

970

971 **Response Behavior: Calling 911**

972

973 **Quantitative Results**

974 Overall, 911 was called in 16.4% (n=903 out of 5,521) of ORE reports (Table 1, Figure 11).
975 When 911 was called, EMS arrived half the time, or 49.2% of reports (n=444 out of 903, with
976 0.3% missing). Segmented regression identified December 2017 as a changepoint after which
977 calls to 911 decreased considerably; during the last 6 months of the observation period, 911
978 was called in only 5.4% of OREs.

979

980 **Programmatic Context**

981 Calling emergency medical services (EMS, i.e., 911) was universally recommended in trainings
982 by Prevention Point Pittsburgh. However, fear of criminal prosecution is expected to have
983 dampened the likelihood of this behavior. The Pennsylvania “Good Samaritan” Act 139 was
984 enacted in December 2014, offering limited criminal immunity for minor drug possession
985 charges when calling EMS during an overdose [59]. In spline regression, comparing before and
986 after the law change (Figure S17), there appears to have been a transitory increase in calls to
987 911, which was not sustained over time. Program staff also stated that people who do not use
988 drugs are more likely to call 911, and increases in dispensing naloxone outside of networks of
989 people who use drugs in the years after state legislation enactment could have contributed to
990 the transitory increase in 911 calls.

991

992 Program staff offered explanations to account for the surprisingly low rate of EMS arrival, based
993 on conversations during the ORE report intake that were not quantified on forms. The common
994 theme was wanting to avoid encountering first responders (which could include police) unless
995 absolutely necessary, especially in the context of drug-induced homicide laws as documented
996 elsewhere [60]. Successful reversals may have resulted in a follow-up call to 911 stating that
997 EMS were no longer required. The reporter may have called EMS, administered naloxone, and
998 then left the scene, and therefore may not know for certain if EMS arrived. For these reasons,
999 program staff cautioned in the interpretation of the seemingly low rate of EMS arrival in these
1000 data.

1001

1002 **Response Behavior: Hospital Transport**

1003

1004 **Quantitative Results**

1005 Among the 5,521 ORE reports, hospital transport was reported in 5.0% (n=274) of OREs. No
1006 temporal changepoint was detected in segmented regression, Table 2. Visual inspection of the
1007 time trend revealed heavy concentration of zeros (e.g., no hospital transport) in the first 11
1008 years of the observation period (Figure 11). The last six months of the observation period
1009 suggested an uptick, with 7.7% (95% CI: 3.3%, 12.0%) of OREs having had hospital transport.

1010

1011 **Programmatic Context**

1012 Empirical data show that hospital transport had a sudden peak in 2017 [61]; program staff
1013 pointed out that this was the year with peak overdose deaths in Allegheny County, as well being
1014 contemporaneous with the brief emergence of carfentanil in the unregulated drug supply.
1015 Additionally, based on interviews during ORE reports, program staff suggested that emergence
1016 of xylazine in 2022 may have led to more hospital transport due to lack of reanimation.

1017

1018 **Adverse Events**

1019

1020 Granular information on specific adverse events (AEs) was recorded systematically starting in
1021 August 2016 and are thus available for 4,606 ORE reports, which constitutes the denominator
1022 for rate calculations. Any adverse event was noted in 31.4% (n=1,446/4,606) of OREs. Overall,
1023 emesis (vomiting), anger, and “feeling sick” were the most commonly reported adverse events.
1024 Annualized time trends in AE counts and rates per OREs are displayed in Figure 12 for the 6
1025 calendar years (2017-22) with complete reporting. The two most common AEs (Table 4)
1026 described in free text notes were confusion (n=11) and diarrhea (n=4), which only were reported
1027 with the 1 mL vial. There was no indication in free text fields for wooden chest syndrome,

1028 muscle rigidity, laryngospasm, or pulmonary edema, which are other adverse events of concern
1029 with illicitly manufactured synthetic opioids.

1030

1031

1032 **Figure 12. Annual counts and percents of adverse events following naloxone administration.** Vertical bars are
1033 counts of adverse event reports by year. Green lines are percents of overdose response events annually (N=4,606
1034 total), enumerated on the right vertical axis.

1035

1036 OREs in which adverse events were reported had slightly higher average naloxone doses 1.66
1037 (95% CI: 1.62, 1.71) compared with all OREs 1.59 (95% CI: 1.56, 1.61). More than one dose of
1038 naloxone was associated with higher incidence of any reported adverse event, 47.3% of OREs
1039 (n=685/1,446), compared to 40.7% (n=1,287/3,160) of OREs when one or fewer doses were
1040 administered (Wald $\chi^2=17.8$, 1 df, $p<0.001$), a rate difference of 6.6 per 100 OREs (95% CI: 3.5,
1041 9.7).

1042

1043 **Adverse Events: Emesis**

1044

1045 **Quantitative Results**

1046 Emesis (vomiting or “puking”) was reported in 13.2% (n=607) of OREs, but differed (Wald χ^2
1047 108, 2 df, $p<0.001$) considerably by formulation. OREs using the 4 mg nasal spray were twice
1048 as likely to result in emesis compared to the 1 mL vial (20.8% versus 9.6%), Table 4. After
1049 adjusting for doses administered, there were 106 (95% CI: 82, 130) more emesis events per
1050 1,000 OREs with the 4 mg nasal spray than the 1 mL vial at 0.4 mg/mL.

1051

1052

Table 4. Adverse events reported after naloxone administration, by formulation and dose, August 2016 to January 2023.

		Naloxone Formulation				Doses Administered				
		Total	1 mL vial	Nasal 4 mg	Multiple Forms	Wald Test*	Average Doses (95% CI)	Cases >1 Dose	Percent of Cases > 1 Dose	
All Reversals		4,606	3,082	1,373	151		1.59 (1.56, 1.61)	1,972	43.6%	
Reversals with any AE recorded below		1,446	820	557	69		1.66 (1.62, 1.71)	685	47.8%	
Emesis	Cases	607	296	284	31	x2 108, p<0.001	1.73 (1.65, 1.81)	308	50.7%	
	(Percent) or Rate per 1,000 Reversals	(13.2%)	96.2	207.6	205.3					
	Rate Difference per 1,000 reversals relative to 1 mL vial, adjusted for dose			ref	+106	+90.3				
	Rate difference 95% CI				+82.0, +130	+22.6, +158				
Angry	Cases	546	314	206	31	x2 31, p<0.001	1.61 (1.53, 1.68)	237	43.4%	
	(Percent) or Rate per 1,000 Reversals	(11.9%)	102.1	150.6	205.3					
	Rate Difference per 1,000 reversals relative to 1 mL vial, adjusted for dose			ref	+48.5	+103				
	Rate difference 95% CI				+47.8, +49.2	+101, +105				
Felt Sick	Cases	440	291	136	18	x2 1.1, p=0.56	1.58 (1.50, 1.67)	186	42.3%	
	(Percent) or Rate per 1,000 Reversals	(9.6%)	94.6	99.4	119.2					
	Rate Difference per 1,000 reversals relative to 1 mL vial, adjusted for dose			ref	+4.8	+24.6				
	Rate difference 95% CI				+4.2, +5.4	+22.8, +26.4				

Death	Cases	47	24	20	3	x2 5.6, exact p=0.043	1.94 (1.63, 2.24)	29	61.7%
	(Percent) or Rate per 1,000 Reversals	(1.02%)	7.8	14.6	2.0				
	Rate Difference per 1,000 reversals relative to 1 mL vial, adjusted for dose		ref	+4.5	+8.4				
	Rate difference 95% CI			-2.6, +11.6	-14.9, +31.6				
Shaking	Cases	33	27	5	1	x2 10.5, exact p=0.005	1.97 (1.50, 2.43)	21	63.4%
	(Percent) or Rate per 1,000 Reversals	(0.7%)	8.8	3.7	6.6				
	Rate Difference per 1,000 reversals relative to 1 mL vial		ref	-5.1	-2.1				
	Rate difference 95% CI			-5.0, -5.3	-1.7, -2.6				
Confusion**	Cases	11	11	0	0		2.36 (1.40, 3.32)	8	72.7%
	Rate per 1,000 Reversals		3.6						
Diarrhea**	Cases	4	4	0	0		1.25 (0.45, 2.0)	1	25.0%
	Rate per 1,000 Reversals		1.3						

* Model-based Wald chi-square test with 2 df. Fisher's Exact test was used if any cell count was less than 10.

** Interpret with caution. Derived from free text notes, not recorded on structured form.

1054 In both absolute and relative (to OREs) rates, Figure 12, emesis increased as a reported
1055 adverse event from 2017 to 2022. In the era when only 1 mL vials were distributed, about 16%
1056 of ORE involved emesis, going up to about 23% when naloxone distribution included vials and 4
1057 mg nasal spray both, contemporaneous also with the advent of illicitly manufactured fentanyl.

1058

1059 **Programmatic Context**

1060 Prevention Point Pittsburgh staff noted that emesis was the most objectively observable
1061 adverse event, and that it would be more likely to be reported than other more subjective
1062 adverse events, impacting interpretation of relative prevalence between AEs. But they did not
1063 identify a reason why reporting of emesis would be different between formulations, providing
1064 credence to inter-formulation comparisons.

1065

1066 **Adverse Events: Anger**

1067

1068 **Quantitative Results**

1069 Anger was reported in 11.9% of OREs (n=546/4606) and differed by formulation (Wald χ^2 108,
1070 2 df, $p < 0.001$). The 1 mL vial was associated with fewer angry AE reports, at 10.2%, compared
1071 to 15.1% of OREs with the 4 mg nasal spray, Table 4. After adjusting for doses administered,
1072 per 1000 OREs there were 48.5 (95% CI: 47.8, 49.2) additional cases of anger after
1073 administration of the nasal spray.

1074

1075 In both absolute and relative measures, anger after naloxone administration was most reported
1076 in 2020, during the phases of COVID-19 pandemic isolation. However, even though 4 mg nasal
1077 spray supplanted 1 mL vials during a sudden injectable naloxone supply shortfall in 2021-22
1078 (Figure 5), reports of anger after naloxone administration returned to pre-pandemic levels

1079 despite the formulation change. This shortfall was the result of manufacturing difficulties at the
1080 single manufacturer that supplied the Naloxone Buyers Club, resulting in nationwide lack of
1081 availability for harm reduction programs [62].

1082

1083 **Programmatic Context**

1084 Prevention Point Pittsburgh staff cautioned that if someone was vomiting, they may not be able
1085 to simultaneously express anger, and therefore the reported numbers are likely an undercount
1086 of experience. Perceptions of what constitutes anger could also be subjective, and in very rare
1087 cases extreme, with confrontational action against the person reversing the overdose. But they
1088 did not identify reasons why reporting would be different by formulation.

1089

1090 **Adverse Events: “Felt Sick”**

1091

1092 **Quantitative Results**

1093 “Felt sick” was understood by participants to mean “dopesick” from precipitated opioid
1094 withdrawal. Cumulatively, 440 cases of “feeling sick” were reported, in 9.6% of OREs (Table 4).
1095 The incidence rate difference between formulations was negligible.

1096

1097 Adverse events where the recipient “felt sick” were highest in 2019, in nearly 25% of OREs, but
1098 highest in terms of absolute number (about 175 per year) in 2020, Figure 12. There was a drop
1099 in reports of “feeling sick” in 2021-2.

1100

1101 **Programmatic Context**

1102 Prevention Point Pittsburgh staff did not have a specific attribution to explain temporal variation
1103 in feeling sick. However, they pointed out that feeling dopesick was a subjective experience that
1104 may not be entirely or objectively observable by the person who administered naloxone and was
1105 providing the ORE report.

1106

1107 **Adverse Events: Shaking**

1108

1109 **Quantitative Results**

1110 Shaking was systematically collected, and was reported in n=33 OREs, and differentially by
1111 formulation: n=27 cases using the 1 mL vial, n=5 with nasal alone, and n=1 with multiple forms
1112 (Fisher's Exact 10.8, 2 df, $p < 0.005$). The incidence rate difference of -5.1 cases (95% CI: -5.0, -
1113 5.3) per 1,000 OREs slightly favored the nasal spray over the 1 mL vial. Shaking was mostly
1114 reported in 2017, Figure 12, with 9 cases, and three or fewer in subsequent years.

1115

1116 **Programmatic Context**

1117 Shaking was interpreted by Prevention Point Staff to be a sign of opioid withdrawal, as opposed
1118 to seizures. No plausible explanation for this phenomenon was offered by Prevention Point
1119 Pittsburgh staff.

1120

1121 **Adverse Events: "Was Okay" versus Death**

1122

1123 **Quantitative Results**

1124 Participants presenting for refills had been asked if the person on whom naloxone was
1125 administered “was okay” after the ORE, to the best of their knowledge, since the start of study
1126 observation. This category is conceptually understood to encompass survivorship, even if
1127 hospital transport or adverse events occurred, and serves as a contextual adjunct to deaths.
1128 Cumulatively, in 5,449 out of 5,521 reports (98.7%) from 2005 to 2023, the participant felt
1129 confident enough to respond. The person on whom naloxone had been used was judged to be
1130 “okay” 98.0% of the time (n=5,340/5,449 among the three dominant naloxone formulations).
1131 Differences by formulation were observed (Pearson χ^2 32.7, 3 df, p<0.001), but were small:
1132 98.5% okay with 1 mL vial, 99.2% with 10 mL vial, 96.4% with 4 mg nasal spray, and 95.4%
1133 with multiple forms.

1134

1135 Death as an adverse event was collected from 2016 onwards. There were 47 out of 4,606
1136 reports (1.0%) of death following naloxone administration.

1137

1138 **Programmatic Context**

1139 Program staff had strong cautions about interpretation of deaths following naloxone
1140 administration. The death case review provides additional context below. In addition, program
1141 staff felt that as the volume of naloxone distributed has increased within networks of people
1142 using drugs together, there should be increased likelihood of someone at the scene carrying
1143 naloxone. Therefore, they interpreted deaths following naloxone administration as an indirect
1144 indicator of people who had been using drugs alone. Forced isolation during the first year of the
1145 COVID pandemic provided an opportunity to test this hypothesis, as described below.

1146

1147

1148 **Death Case Review**

1149

1150 **Quantitative Results**

1151 From 2020 through 2022, encounter notes with contextual information were available for 22 out
1152 of 23 deaths. In 18 cases the person was found “too late” after death for naloxone to be
1153 effective, for example the morning after an overdose that had likely occurred the previous
1154 evening. In three cases, paramedics told the reporter that there was an alternative cause of
1155 death other than overdose. In one instance, a reporter said that police had not allowed her to
1156 administer the naloxone that she was carrying, and the person died.

1157

1158 Quantitative AE data allowed empiric corroboration that deaths increased during the height of
1159 pandemic isolation. Most years, 5 or fewer deaths were reported, Figure 13. However, in 2020,
1160 the annual reports tripled in both absolute and relative terms. This single-year increase
1161 paralleled the time-trend with AEs for anger, but with much lower sample size.

1162

1163 **Figure 13. Annual counts and percents of deaths reported.** Vertical bars are counts of adverse event reports by
1164 year. Green lines are percents of overdose response events annually (N=4,606 total), enumerated on the right
1165 vertical axis.

1166

1167 **Programmatic Context**

1168 Program staff posited that, under the assumption that using drugs alone was more common
1169 during forced social isolation and quarantine periods of the first year of the COVID-19
1170 pandemic, people who had overdosed may have been less likely to have been found for timely
1171 action. Alternatively, additional respiratory compromise stemming from viral infection could be a
1172 plausible contributory cause. Overwhelmed EMS during the early pandemic could also in part
1173 explain the single year increase in reported deaths. Program staff emphasized that they did not
1174 experience a drop in service provision during COVID and increased how much supplies were

1175 distributed per visit to reduce the need for return visits, as well as providing additional services
1176 (food, clothing, etc.) to meet community needs.

1177

1178

1179 **Adverse Events and Dose Titration**

1180

1181 During the period where AE information was being systematically recorded (2016 onwards), the
1182 1 mL vial offers a unique opportunity to conceptually explore dose-response between naloxone
1183 dose and adverse events. The expectation was that naloxone dose titration would result in
1184 fewer adverse events. Titration was defined as reporting fractional dosing (n=117 OREs), and
1185 non-titration was defined as integer doses of naloxone administered (n=2,953 OREs). This
1186 imperfect exploratory measure deserves reiteration of the caveat for misclassification: Two half
1187 doses administered separately would be reported as 1.0 dose, but in this simple metric would
1188 be misclassified integer dosing. This is expected to bias towards the null.

1189

1190 Titration of naloxone was recorded in only 4.0% of OREs, but titration of naloxone showed
1191 favorable incidence rate ratios (IRR) for the three most common adverse events (Table S2).
1192 Titration was associated with less emesis IRR=0.26 (95% CI: 0.084, 0.80; Wald χ^2 2.36,
1193 $p=0.018$), less anger IRR=0.081 (95% CI: 0.011, 0.57; Wald χ^2 2.5, $p=0.012$), and less “feeling
1194 sick” IRR=0.44 (95% CI: 0.186, 1.051; Wald χ^2 3.8, $p=0.051$). Death and shaking also showed
1195 favorable tabular distributions for titration, but model-based IRRs could not be computed due to
1196 zero cell counts.

1197

1198

1199 **DISCUSSION**

1200

1201 Community naloxone distribution at Prevention Point Pittsburgh resulted in more than five
1202 thousand reported overdose response events, over 17 years. However, previous studies of
1203 community naloxone distribution are of short duration, providing limited insight into program
1204 implementation and evolution. In addition, the preponderance of real-world data on overdose
1205 reversal with naloxone has originated from emergency medical settings and hospitals, leaving a
1206 gap in the increasingly common practice of community overdose response. Therefore, this
1207 comprehensive report includes key findings from both implementation and biomedical
1208 perspectives.

1209

1210 In this sample of individuals returning to a harm reduction program for naloxone refills, the
1211 majority of reported OREs indicated success (i.e., the person survived), even in recent years
1212 with fentanyl, xylazine, and methamphetamine prevalent in the local drug supply. A minority, but
1213 not a trivial proportion, had adverse events suggesting precipitated withdrawal.

1214

1215 **Research Questions 1 & 2: Naloxone Utilization after Law** 1216 **Change**

1217

1218 State law changes at the end of 2014 were intended to remove barriers to naloxone distribution
1219 for harm reduction programs, thereby enabling the intervention to reach broader populations.

1220 The key programmatic finding was that enabling state legislation alone was insufficient to
1221 expand services to populations at greatest risk for overdose [45]. Before the law change, which
1222 expanded legal protections and relaxed prescribing policies, Prevention Point Pittsburgh served
1223 a predominantly White network of people who used heroin, a cohort that remained steady and
1224 aged over time. While enabling legislation in 2015 led to greater naloxone dispensing volume

1225 (10.4 doses per month to 65.9 per month in the year that followed), ORE report volume did not
1226 keep apace: ORE per new participant fell from 1.46 to 0.47 in the year before versus after the
1227 law change. Demographic characteristics offer explanations. In the year after the law was
1228 enacted, new participants were more likely to be older (average age increasing from 37 to 46
1229 years-old), more female (increasing from 35% to 58%), and family or friends of people who use
1230 drugs, a marked shift. Compared to a previous evaluation of Prevention Point data, our
1231 observations are consistent: After enabling legislation, the earlier analysis found that these
1232 demographically different new participants were only 0.04 times as likely to reverse an overdose
1233 compared to people who use drugs [16]. Instead, refocusing distribution directly to networks of
1234 people who use drugs required programmatic effort and intentionality including hiring people
1235 from target communities, providing safer smoking supplies, and starting mobile buprenorphine
1236 induction services.

1237
1238 During the first decade of naloxone distribution and before the 2015 enabling legislation, the
1239 most common response to whom naloxone was administered was “friend or acquaintance.” This
1240 could reflect social desirability bias due to the stigmatized nature of the intervention at the time,
1241 and fear of revealing that the participant had transferred the naloxone to someone to whom it
1242 had not been prescribed. Naloxone reversals were concentrated within social networks: 81% of
1243 OREs were performed on friends and acquaintances, not the person to whom it had been
1244 prescribed. Less than 5% was used on family members or the individual who reported the ORE.
1245 Interestingly, the percent of reversals on the reporter themselves (i.e., the person prescribed the
1246 naloxone) was twice as high for nasal sprays (16.9%) than for injectable (8.5% 10mL vial, 5.9%
1247 1mL vial) formulations.

1248
1249 Monthly ORE rates (per 100 doses dispensed, or number of new participants, Figure 3) offer
1250 new possibilities for tracking the impact of policy or programmatic changes in naloxone

1251 distribution. ORE per new participants closely reflects the observations of program staff during
1252 corresponding time periods; although the metric is useful for retrospective analysis, it confirms
1253 what the program already knew from their direct care provision experience. In addition, time
1254 series of OREs per 100 doses dispensed also showed obvious peaks when there were
1255 fluctuations in the drug supply, namely the emergence of illicitly manufactured fentanyl and
1256 carfentanil. We suggest that these metrics may be useful in future epidemiologic studies and
1257 serve as a useful tool for programs to monitor. However, drawing from the research team's
1258 national experience providing technical assistance, we also acknowledge that reversal record
1259 keeping requirements from funders can be a considerable impediment to actual service delivery.
1260 Therefore, we feel that data utility should be secondary to naloxone distribution, and the former
1261 should not impede the latter.

1262

1263 **Research Question 3: Racial Identity of New Participants**

1264

1265 Addressing our third research question, as overdose death rates in underserved racialized
1266 minority communities began to increase, the program intentionally fostered new mobile outreach
1267 sites in January 2016, and started distributing safer smoking supplies that met the needs of that
1268 community. Black racial identity of new participants increased from 27% to 39%. These
1269 innovations led to significantly more naloxone distribution *and* ORE reports. However, time-
1270 series evaluation identified an inflection point in December 2020 after which the share of White
1271 participants increased. Programmatic context revealed that this was due to expansion of mobile
1272 services to additional neighborhoods to provide on-demand buprenorphine treatment for opioid
1273 use disorders, where take-home naloxone was also provided. Racial disparities in the uptake of
1274 buprenorphine services have been well-documented [63,64], and are known to have been
1275 exacerbated during the COVID pandemic [65]. These national trends and the experience at

1276 Prevention Point Pittsburgh are consistent. The findings suggest that new targeted
1277 programmatic strategies will be needed to expand medication assisted treatment to
1278 communities of color.

1279

1280 **Research Questions 4 & 5: Doses per Overdose Response**

1281 **Event**

1282

1283 Per our fourth and fifth research questions, we found that the average doses of naloxone
1284 needed to reverse an overdose has not changed over time (segmented regression change point
1285 $p=0.60$); however, formulation effects were also observed. In the first decade of operation when
1286 overdoses were predominantly due to heroin, distribution of 10 mL naloxone vials resulted in an
1287 average of 1.85 doses per ORE. When naloxone distribution shifted to single-unit packaging,
1288 coincident with the appearance of illicitly manufactured fentanyl in the local drug supply [46],
1289 average doses were lower: 1.51 doses per ORE with the 1 mL vials, and 1.63 doses with the 4
1290 mg nasal spray. Utilization implications for single- versus multi-dose packaging for liquid
1291 pharmaceuticals has been explored in the context of image contrast media [66] and vaccines
1292 [67], but has not been previously described for naloxone. However, studies on formulation
1293 preference between injectable and nasal forms of take-home naloxone have revealed mixed
1294 desires among the target population [68], and the current programmatic recommendation is to
1295 offer both. Programmatic context in our study revealed that preferences are not static within an
1296 individual and are related to how might be used: injectable for home and to be used on
1297 themselves, versus nasal spray for carrying in a purse to be used on others. Higher dose
1298 naloxone products were not evaluated in this study, but have been described elsewhere [69,70].
1299 It is worth contextualizing dosing trends as the overdose epidemic evolved from one of
1300 prescription opioids to heroin, and from heroin to fentanyl – three periods defined as a “triple

1301 wave” phenomenon [1]. Using state Allegheny County inflections in fatal and non-fatal
1302 overdose to define these waves [71,72], average naloxone per ORE decreased from 1.92
1303 (95%CI: 1.79, 2.05) in the first wave (2008-2011) to 1.57 (95% CI: 1.50, 1.64) in the second
1304 wave (2012-2015), then remained stable between the second and third (2016-2023) waves
1305 (1.60 doses, 95% CI: 1.57, 1.63). These data may be partly confounded by formulation trends
1306 discussed above; further investigation into the relationship between the drug supply and ORE
1307 behaviors is warranted.

1308
1309 There was also an uptick in doses per ORE administered in 2022, as xylazine entered the local
1310 drug supply [73]. Average dose of naloxone in 2021 was 1.67 (95% CI: 1.58, 1.75) increasing to
1311 1.75 (95% CI: 1.67, 1.84) in 2022. Additional doses may have been administered because lack
1312 of reanimation even if respiration was restored. Program staff adapted to this circumstance by
1313 emphasizing counting breaths before administering more naloxone, and specifically counselling
1314 respondents who reported using more than two doses. The influence of xylazine on community-
1315 based naloxone administration practice needs further research.

1316

1317 **Research Question 6: Calling 911**

1318

1319 We found that 911 was only called in 16% of ORE reports across the 17.6 year observation
1320 period. There was a transient increase in calls to 911 after enactment of the Good Samaritan
1321 law in January 2015, but by December 2017 the proportion dropped considerably, so much so
1322 that in the last 6 months of observation, less than 6% of OREs involved calling 911. There is
1323 ample evidence that people who use drugs remain fearful of arrests [74–77] when calling 911,
1324 despite the Good Samaritan law. Other possible factors that could be considered include the
1325 perception that there is no need for further treatment, fear of getting additional naloxone from

1326 uniformed first responders, stigma, cost, and wanting to use again because of withdrawal
1327 symptoms. The observed reluctance to call 911 also has implications when considering data
1328 derived from EMS and other medical encounters, given that these represent an unknown
1329 fraction of actual overdose reversals and are therefore a selected sample that may not be
1330 representative of all reversal events, in terms of formulations, doses, AEs, and outcomes.

1331

1332 **Research Question 7: Deaths**

1333

1334 Research question 7, which addressed circumstances surrounding deaths, was examined using
1335 empirical findings and narrative review of reports of deaths. Most deaths (18 out of 23) occurred
1336 when the person was found “too late” to intervene. We were able to observe that deaths peaked
1337 in 2020 during the isolation phase of the COVID pandemic. Program staff emphasized that in all
1338 their years working in this program, they are not aware of any participants stating that they had
1339 administered naloxone but the person still died because they did not have enough naloxone.
1340 There were 4.5 per 1,000 OREs more deaths reported with the nasal spray than 1 mL vial;
1341 however, strong cautions are warranted about drawing conclusions because using alone and
1342 being discovered “too late” could confound the empirical observation.

1343

1344 **Research Question 8: Adverse Events and Titration**

1345

1346 Per research question 8, concerning the relationship between formulation or dose titration and
1347 adverse events, we found significant differences by formulation for the most common AEs,
1348 emesis and anger. Per 1,000 OREs, there were 106 additional reports of emesis with the 4 mg
1349 nasal spray compared to 1 mL vials; for anger, there were 48 additional reports per 1,000

1350 OREs. Events of wooden chest syndrome and stiffness, related to synthetic opioid exposure,
1351 were not reported in this study.

1352

1353 **Limitations**

1354

1355 This study has several limitations that should be considered. It represents the experience of a
1356 single harm reduction program and, per the EMI framework, study results are not generalizable
1357 to other community settings or cities. Self-reported interview data are subject to recall bias, with
1358 respondents potentially more likely to remember extreme or negative events. Participant reports
1359 were from laypersons without medical training, and reporting of adverse events may have
1360 varying accuracy. Naloxone obtained from other sources in Pittsburgh are not captured in
1361 dispensing data. While it is possible that the same overdose event may be reported by the
1362 person who administered naloxone as well as the person to whom it was administered, this is
1363 unlikely because *refills* were recorded. It was not possible to link to hospital or vital statistics in
1364 this anonymized dataset. There was no way to observe the counterfactual, namely what would
1365 have happened if the antidote had not been administered; some overdoses may have been self-
1366 resolving without naloxone administration. Despite these limitations, the detailed quantitative
1367 and programmatic context documented provide a broad historical perspective on naloxone
1368 distribution and use.

1369

1370 Finally, we acknowledge that record keeping of OREs has been contentious among harm
1371 reduction programs because it can place substantial administrative burden on staff that detracts
1372 from their ability to distribute naloxone and provide other direct services. By adopting the
1373 collaborative EMI process, we present an alternative model whereby important programmatic

1374 considerations and quantitative insights are given equal credence, and where the research
1375 questions are mutually agreed upon.

1376

1377 **Policy Implications**

1378

1379 Our findings suggest five policy implications. First, enabling legislation to expand naloxone
1380 access is necessary but insufficient alone to reach those at highest risk for overdose. Laws and
1381 policies intended to expand community-based naloxone distribution should consider what
1382 additional practical support is required to reach the underserved. In this example from
1383 Prevention Point Pittsburgh, outreach to underserved communities and high-risk populations
1384 represent deliberate strategies that were enabled by the legislation. Diversification of harm
1385 reduction services beyond naloxone and provision of sterile injecting equipment can also
1386 increase naloxone dispensing, such as occurred in this setting with the inclusion of safer
1387 smoking supplies and mobile buprenorphine services. These program adaptations are
1388 consistent with national trends; the Centers for Disease Control & Prevention recently reported
1389 that smoking has supplanted injection as the route of administration most often implicated in
1390 overdose death [78].

1391

1392 Second, enabling legislation in Pennsylvania led to a decrease in naloxone being confiscated by
1393 law enforcement, but one death was reported following an incident in which someone carrying
1394 naloxone was prohibited by police from administering it. In addition, reports of excessive
1395 additional doses administered by EMS and police after successful revival by peers should be
1396 investigated. EMS policy and protocols should be re-evaluated in the context of bystander
1397 administration to ensure naloxone dosing conforms to evolving medical best practice.

1398

1399 Third, the Good Samaritan law appeared to have an observable but time-limited effect on
1400 increasing calls to 911. These state laws may need to be revised if they are to be more
1401 effective. The very low rate of calling 911 in recent years bears further investigation [79], such
1402 as to clarify when support services are most medically necessary, and identify social and legal
1403 barriers including the impact of drug-induced homicide laws [80]. These investigations will be
1404 crucial in the context of over-the-counter naloxone, which has explicit instructions to call 911.
1405
1406 Fourth, consistent with previous analyses [16,19,81], we found that 1 mL vials injected
1407 intramuscularly were effectively used in thousands of reversals. Certain adverse events were
1408 lower than with the 4 mg nasal spray, but participants expressed a desire for both injectable and
1409 nasal formulations. Given historical fluctuations in funding for and availability of naloxone,
1410 program participants would be best served knowing how to use both types of naloxone, and
1411 policies, standing orders, and laws should allow parity in access between different formulations.
1412 Differences in adverse event profiles between naloxone formulations [69,70] may be of
1413 relevance to policymakers. The behavior of titrating doses of naloxone to prevent adverse
1414 events also suggests that there may be underrecognized demand for formulations that deliver
1415 smaller or fractional doses, and reinforces the policy importance of ensuring that multiple forms
1416 of naloxone are available. Education on dose titration within harm reduction programs may also
1417 be an opportunity to prevent or reduce adverse events.
1418
1419 Fifth, sharing of naloxone between participants is a natural phenomenon, especially when
1420 provided at no cost to the participant. While secondary distribution of sterile syringes has been
1421 extensively studied in many countries [82–86], corresponding studies for naloxone distribution
1422 have not been published. Primary encounters with harm reduction staff provide opportunity for
1423 additional services to be offered (not just drug-related), a benefit that is attenuated through
1424 secondary distribution. Furthering this trend, over-the-counter versions of naloxone nasal sprays

1425 were approved by FDA in 2023, naloxone-dispensing vending machines are rapidly expanding
1426 [87], and mail order naloxone distribution has been established on a national scale [88],
1427 eschewing the direct human connection necessary for the comprehensive harm reduction
1428 services like Prevention Point Pittsburgh have traditionally provided. Concerted policy,
1429 technology, telehealth, and communication innovations could supplement these innovative
1430 distribution channels to re-establish more comprehensive care possibilities in an era where
1431 naloxone distribution is becoming more indirect. As demonstrated by the rich programmatic
1432 context in this paper, traditional harm reduction programs possess a depth of untapped applied
1433 experience that can inform broader policy and regulatory decisions.

1434

1435 **Future Research Needs**

1436

1437 Severe precipitated withdrawal should not be dismissed as an “unavoidable” adverse event
1438 expected to occur in some OREs using antagonists, but rather needs to be studied
1439 independently, especially as it could lead to short- and long-term changes in behavior that
1440 increase risk for subsequent overdose; further research is needed to determine how withdrawal-
1441 related AEs can be reduced. For example, severe withdrawal can lead to immediate and
1442 repeated re-dosing with opioid agonists. In the weeks that follow an ORE, negative withdrawal
1443 experiences could also lead to use of street drugs alone. Co-author and Prevention Point Staff
1444 member MV shared testimony at a scientific conference articulating this connection. He had
1445 overdosed on heroin among strangers who administered 3 doses of naloxone, and he then
1446 received multiple unknown additional doses from uniformed first responders. He felt very
1447 anxious and was vomiting so frequently he had trouble breathing: “I tried to re-dose with heroin
1448 every 15 minutes to feel anything other than this horrible feeling. For months after that bad

1449 overdose, I was super hesitant to use around others. I mostly wanted to use alone to avoid
1450 something like that from happening again which put me at great risk.” [89]

1451
1452 To empirically establish post-overdose behavioral consequences, validated and easy-to-use
1453 outcome measures for overdose severity and response could be developed. Randomized field
1454 studies, such as comparing formulations of opioid antagonists, could also provide empirical
1455 evidence to inform policy and local purchasing decisions. Further research may also be
1456 warranted into other factors at the pharmaceutical formulation level, in terms of
1457 pharmacokinetics or packaging. And finally, training on timing and titration of dose
1458 administration and rescue breathing all bear scientific scrutiny. Qualitative studies involving
1459 those with lived experience should be considered to bring light to dimensions of community-
1460 based naloxone distribution and bystander naloxone administration that are not observable
1461 quantitatively [90,91]. Regardless of the method, there is pressing need for this type of work to
1462 more fully understand unmet needs in a changing environment.

1463

1464 **CONCLUSION**

1465

1466 This comprehensive analysis of a harm reduction program reveals that while enabling state
1467 legislation can create the environment for expanded naloxone distribution, when naloxone is
1468 distributed to people not at risk of overdose or their immediate social networks, increases in
1469 dispensing volume can become negatively decoupled from actual administration and overdose
1470 reversal. Expanding services to underserved communities requires additional innovation. We
1471 also found that the long-term consistency of less than 2 doses per ORE, high survival rate, and
1472 robust utilization all lend confidence in prioritizing naloxone distribution directly to people who

1473 use drugs. Finally, we found lower rates of adverse events with lower doses of naloxone,
1474 titration, and with injectable intramuscular formulations. Collectively, these findings can help re-
1475 prioritize community-based naloxone distribution to those most likely to use the antidote to
1476 reverse an opioid overdose.

1477 **ACKNOWLEDGEMENTS**

1478 We thank the participants of Prevention Point Pittsburgh for their work in reversing opioid
1479 overdoses. We are indebted to Dan Bigg and staff at the Chicago Recovery Alliance who
1480 provided free naloxone to Prevention Point Pittsburgh in early years of this study and originated
1481 this intervention. We thank LaMonda Sykes, Bridgette Mountain, and Natalie Sutton for
1482 administrative support at UNC. We thank Alex Bennett and Tiffany Fitzpatrick for helping to
1483 implement naloxone distribution quickly in 2005 when overdose deaths began to spike from
1484 fentanyl in the opioid supply. Additional FDA project workgroup members included Mallika
1485 Mundkur, Tamra Meyer, Candice Collins, Chi-Ming (Alice) Tu, Celia Winchell, Bic Nguyen,
1486 Nushin Todd, Srikanth Nallani, Rigoberto Roca, Blair Coleman, Sanae Cherkaoui.

1487
1488 **TRIAL REGISTRATION**

1489 This investigation was pre-registered osf.io/b2f4h

1490
1491 **CODE AND DATA SHARING STATEMENT**

1492 Pre-registration: DOI osf.io/b2f4h. Codebook, data collection form, and analytic code: DOI
1493 osf.io/sq5d6. Data were provided by Prevention Point Pittsburgh and are used with permission.
1494 Due to the sensitive nature of syringe service provision, and the risk of deductive disclosure, the
1495 decision was made to not make the data public. Interested parties can contact Alice Bell at
1496 Prevention Point Pittsburgh for collaboration and data requests.

1497
1498 **CONTRIBUTORSHIP STATEMENT**

1499 ND, AB, MDS, EW, MN, AS, DC, ZD, and AM contributed to study conceptualization and
1500 design. AB and MV (and other Prevention Point Pittsburgh staff) conducted data collection and
1501 entry, and provided operational context. ND conducted the statistical analysis and is solely
1502 responsible for data integrity. All authors contributed to result interpretation and manuscript
1503 development.

1504
1505

1506 **REFERENCES**

- 1507
- 1508 1. Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic
1509 Determinants. *Am J Public Health*. 2018;108: 182–186. doi:10.2105/AJPH.2017.304187
- 1510 2. Dasgupta N, Creppage K, Austin A, Ringwalt C, Sanford C, Proescholdbell SK. Observed
1511 transition from opioid analgesic deaths toward heroin. *Drug Alcohol Depend*. 2014;145:
1512 238–241. doi:10.1016/j.drugalcdep.2014.10.005
- 1513 3. Jones CM, Bekheet F, Park JN, Alexander GC. The Evolving Overdose Epidemic: Synthetic
1514 Opioids and Rising Stimulant-Related Harms. *Epidemiol Rev*. 2020;42: 154–166.
1515 doi:10.1093/epirev/mxaa011
- 1516 4. D’Orsogna MR, Böttcher L, Chou T. Fentanyl-driven acceleration of racial, gender and
1517 geographical disparities in drug overdose deaths in the United States. Nazif-Munoz JI,
1518 editor. *PLOS Glob Public Health*. 2023;3: e0000769. doi:10.1371/journal.pgph.0000769
- 1519 5. Ovalle D. In grim milestone, U.S. overdose deaths top 100,000 for third straight year.
1520 *Washington Post*. 15 May 2024. Available:
1521 <https://www.washingtonpost.com/health/2024/05/15/opioid-deaths-100000/>. Accessed
1522 16 May 2024.
- 1523 6. Mann, Brian. U.S. drug deaths declined slightly in 2023 but remained at crisis levels. NPR.
1524 15 May 2024. Available: [https://www.npr.org/sections/health-](https://www.npr.org/sections/health-shots/2024/05/15/1251239829/us-drug-overdose-deaths-provisional-2023)
1525 [shots/2024/05/15/1251239829/us-drug-overdose-deaths-provisional-2023](https://www.npr.org/sections/health-shots/2024/05/15/1251239829/us-drug-overdose-deaths-provisional-2023). Accessed 16
1526 May 2024.
- 1527 7. Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, et al. The Effect
1528 of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic
1529 Reviews. *Am J Public Health*. 2021;111: e1–e12. doi:10.2105/AJPH.2021.306306
- 1530 8. Cuadros DF, Branscum AJ, Moreno CM, MacKinnon NJ. Narrative minireview of the spatial
1531 epidemiology of substance use disorder in the United States: Who is at risk and where?
1532 *World J Clin Cases*. 2023;11: 2374–2385. doi:10.12998/wjcc.v11.i11.2374
- 1533 9. Smart R, Pardo B, Davis CS. Systematic review of the emerging literature on the
1534 effectiveness of naloxone access laws in the United States. *Addiction*. 2021;116: 6–17.
1535 doi:10.1111/add.15163
- 1536 10. Freiermuth CE, Ancona RM, Brown JL, Panches BE, Ryan SA, Ingram T, et al. Evaluation of a
1537 large-scale health department naloxone distribution program: Per capita naloxone
1538 distribution and overdose morality. Haj-Mirzaian A, editor. *PLoS ONE*. 2023;18: e0289959.
1539 doi:10.1371/journal.pone.0289959

- 1540 11. Nolen S, Zang X, Chatterjee A, Behrends CN, Green TC, Linas BP, et al. Evaluating equity in
1541 community-based naloxone access among racial/ethnic groups in Massachusetts. *Drug*
1542 *and Alcohol Dependence*. 2022;241: 109668. doi:10.1016/j.drugalcdep.2022.109668
- 1543 12. Naumann RB, Durrance CP, Ranapurwala SI, Austin AE, Proescholdbell S, Childs R, et al.
1544 Impact of a community-based naloxone distribution program on opioid overdose death
1545 rates. *Drug and Alcohol Dependence*. 2019;204: 107536.
1546 doi:10.1016/j.drugalcdep.2019.06.038
- 1547 13. Patel SV, Wenger LD, Kral AH, Sherr K, Wagner AD, Davidson PJ, et al. Optimizing naloxone
1548 distribution to prevent opioid overdose fatalities: results from piloting the Systems
1549 Analysis and Improvement Approach within syringe service programs. *BMC Health Serv*
1550 *Res*. 2023;23: 278. doi:10.1186/s12913-023-09289-8
- 1551 14. Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, et al. Evaluation of a
1552 Naloxone Distribution and Administration Program in New York City. *Substance Use &*
1553 *Misuse*. 2008;43: 858–870. doi:10.1080/10826080701801261
- 1554 15. Drainoni M-L, Koppelman EA, Feldman JA, Walley AY, Mitchell PM, Ellison J, et al. Why is it
1555 so hard to implement change? A qualitative examination of barriers and facilitators to
1556 distribution of naloxone for overdose prevention in a safety net environment. *BMC Res*
1557 *Notes*. 2016;9: 465. doi:10.1186/s13104-016-2268-z
- 1558 16. Bennett AS, Bell A, Doe-Simkins M, Elliott L, Pouget E, Davis C. From Peers to Lay
1559 Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA. *Journal of*
1560 *Psychoactive Drugs*. 2018;50: 240–246. doi:10.1080/02791072.2018.1430409
- 1561 17. Rhodes T, Lancaster K. Evidence-making interventions in health: A conceptual framing.
1562 *Social Science & Medicine*. 2019;238: 112488.
- 1563 18. Wheeler E, Davidson PJ, Jones TS, Irwin KS. Community-based opioid overdose prevention
1564 programs providing naloxone - United States, 2010. *MMWR Morb Mortal Wkly Rep*.
1565 2012;61: 101–105.
- 1566 19. Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH. Characteristics of an Overdose
1567 Prevention, Response, and Naloxone Distribution Program in Pittsburgh and Allegheny
1568 County, Pennsylvania. *J Urban Health*. 2011;88: 1020–1030. doi:10.1007/s11524-011-
1569 9600-7
- 1570 20. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-
1571 administered intranasal naloxone hydrochloride for opioid overdose. *Am J Public Health*.
1572 2009;99: 788–791. doi:10.2105/AJPH.2008.146647
- 1573 21. Albert S, Brason FW, Sanford CK, Dasgupta N, Graham J, Lovette B. Project Lazarus:
1574 community-based overdose prevention in rural North Carolina. *Pain Med*. 2011;12 Suppl
1575 2: S77-85. doi:10.1111/j.1526-4637.2011.01128.x

- 1576 22. Kolbe L, Fins JJ. The Birth of Naloxone: An Intellectual History of an Ambivalent Opioid.
1577 Camb Q Healthc Ethics. 2021;30: 637–650. doi:10.1017/S0963180121000116
- 1578 23. Bohler RM, Freeman PR, Villani J, Hunt T, Linas BS, Walley AY, et al. The policy landscape
1579 for naloxone distribution in four states highly impacted by fatal opioid overdoses. Drug
1580 and Alcohol Dependence Reports. 2023;6: 100126. doi:10.1016/j.dadr.2022.100126
- 1581 24. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing Naloxone to Actively
1582 Injecting Heroin Users: A Program to Reduce Heroin Overdose Deaths. Journal of Addictive
1583 Diseases. 2006;25: 89–96. doi:10.1300/J069v25n03_11
- 1584 25. Campbell ND. Od: naloxone and the politics of overdose prevention. Cambridge, MA
1585 London, England: The MIT Press; 2020.
- 1586 26. Szalavitz M. Undoing drugs: the untold story of harm reduction and the future of
1587 addiction. 2021.
- 1588 27. Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Opioid overdose prevention programs
1589 providing naloxone to laypersons—United States, 2014. MMWR Morbidity and mortality
1590 weekly report. 2015;64: 631.
- 1591 28. Substance Abuse and Mental Health Services Administration. Expansion of naloxone in the
1592 prevention of opioid overdose FAQs. 2014 [cited 29 May 2024]. Available:
1593 [https://www.samhsa.gov/sites/default/files/programs_campaigns/medication_assisted/e](https://www.samhsa.gov/sites/default/files/programs_campaigns/medication_assisted/expansion-of-naloxone-faq.pdf)
1594 [xpansion-of-naloxone-faq.pdf](https://www.samhsa.gov/sites/default/files/programs_campaigns/medication_assisted/expansion-of-naloxone-faq.pdf)
- 1595 29. Health Resources and Services Administration. Rural Access to Emergency Devices –
1596 Opioid Overdose Reversal Grant Program. In: Funding Cycle View [Internet]. 26 Jun 2015
1597 [cited 29 May 2024]. Available:
1598 <https://grants.hrsa.gov/2010/Web2External/Interface/FundingCycle/ExternalView.aspx?fcycleID=e80a781a-769e-4fcb-9372-4f5abbc7998b>
1599
- 1600 30. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for
1601 naloxone: an evaluation of six overdose training and naloxone distribution programs in the
1602 United States. Addiction. 2008;103: 979–989. doi:10.1111/j.1360-0443.2008.02182.x
- 1603 31. Seal KH. Naloxone Distribution and Cardiopulmonary Resuscitation Training for Injection
1604 Drug Users to Prevent Heroin Overdose Death: A Pilot Intervention Study. Journal of
1605 Urban Health: Bulletin of the New York Academy of Medicine. 2005;82: 303–311.
1606 doi:10.1093/jurban/jti053
- 1607 32. Yokell MA, Green TC, Bowman S, McKenzie M, Rich JD. Opioid overdose prevention and
1608 naloxone distribution in Rhode Island. Med Health R I. 2011;94: 240–242.
- 1609 33. Sherman SG, Gann DS, Tobin KE, Latkin CA, Welsh C, Bielenso P. “The life they save may
1610 be mine”: Diffusion of overdose prevention information from a city sponsored

- 1611 programme. *International Journal of Drug Policy*. 2009;20: 137–142.
1612 doi:10.1016/j.drugpo.2008.02.004
- 1613 34. Doe-Simkins M, Wheeler EJ, Figgatt MC, Jones TS, Bell A, Davidson PJ, et al. Naloxone
1614 Buyers Club: Overlooked Critical Public Health Infrastructure for Preventing Overdose
1615 Deaths. 2021. doi:10.1101/2021.11.14.21266221
- 1616 35. LaSane K. For the People: Autonomy and Equity in Naloxone Distribution. [cited 29 May
1617 2024]. doi:10.17615/FA7F-1T13
- 1618 36. Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al.
1619 Opioid overdose rates and implementation of overdose education and nasal naloxone
1620 distribution in Massachusetts: interrupted time series analysis. *BMJ*. 2013;346: f174–f174.
1621 doi:10.1136/bmj.f174
- 1622 37. Coffin PO, Sullivan SD. Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay
1623 Overdose Reversal. *Ann Intern Med*. 2013;158: 1. doi:10.7326/0003-4819-158-1-
1624 201301010-00003
- 1625 38. Coffin PO, Maya S, Kahn JG. Modeling of overdose and naloxone distribution in the setting
1626 of fentanyl compared to heroin. *Drug Alcohol Depend*. 2022;236: 109478.
1627 doi:10.1016/j.drugalcdep.2022.109478
- 1628 39. Xu J, Davis CS, Cruz M, Lurie P. State naloxone access laws are associated with an increase
1629 in the number of naloxone prescriptions dispensed in retail pharmacies. *Drug and Alcohol
1630 Dependence*. 2018;189: 37–41. doi:10.1016/j.drugalcdep.2018.04.020
- 1631 40. Gertner AK, Domino ME, Davis CS. Do naloxone access laws increase outpatient naloxone
1632 prescriptions? Evidence from Medicaid. *Drug and Alcohol Dependence*. 2018;190: 37–41.
1633 doi:10.1016/j.drugalcdep.2018.05.014
- 1634 41. Morrone WR. President’s message: Food and Drug Administration approved naloxone and
1635 continued use of improvised nasal naloxone: What is a treatment advocate and educator
1636 to do? *Journal of Addictive Diseases*. 2016;35: 339–345.
1637 doi:10.1080/10550887.2016.1226582
- 1638 42. Frankel TC. How one company profited while delaying Narcan’s drugstore debut.
1639 *Washington Post*. 18 Sep 2023. Available:
1640 [https://www.washingtonpost.com/business/2023/09/18/narcan-over-the-counter-delays-](https://www.washingtonpost.com/business/2023/09/18/narcan-over-the-counter-delays-emergent-biosolutions/)
1641 [emergent-biosolutions/](https://www.washingtonpost.com/business/2023/09/18/narcan-over-the-counter-delays-emergent-biosolutions/). Accessed 29 May 2024.
- 1642 43. Cohen BR, Mahoney KM, Baro E, Squire C, Beck M, Travis S, et al. FDA Initiative for Drug
1643 Facts Label for Over-the-Counter Naloxone. *N Engl J Med*. 2020;382: 2129–2136.
1644 doi:10.1056/NEJMsa1912403

- 1645 44. Kuehn BM. Easy-to-Use Overdose Antidote Earns Fast-Track Approval. *JAMA*. 2014;311:
1646 1600. doi:10.1001/jama.2014.4483
- 1647 45. Dasgupta N. Analysis of 17 years of naloxone distribution and administration data from
1648 Prevention Point Pittsburgh. 2023 [cited 22 Mar 2024]. doi:10.17605/OSF.IO/B2F4H
- 1649 46. Creppage KE, Yohannan J, Williams K, Buchanich JM, Songer TJ, Wisniewski SR, et al. The
1650 Rapid Escalation of Fentanyl in Illicit Drug Evidence in Allegheny County, Pennsylvania,
1651 2010-2016. *Public Health Rep*. 2018;133: 142–146. doi:10.1177/0033354917753119
- 1652 47. Lancaster K, Rhodes T, Rosengarten M. Making evidence and policy in public health
1653 emergencies: lessons from COVID-19 for adaptive evidence-making and intervention.
1654 *Evidence & Policy*. 2020;16: 477–490. doi:10.1332/174426420X15913559981103
- 1655 48. Satterthwaite FE. An Approximate Distribution of Estimates of Variance Components.
1656 *Biometrics Bulletin*. 1946;2: 110. doi:10.2307/3002019
- 1657 49. Burfoot-Rochford I, Schafft KA. “This Is a Good Neighborhood. This Ain’t No Pittsburgh!”:
1658 Conflicting Narratives of Opioid Misuse within Rural School Districts and Communities.
1659 *American Journal of Education*. 2021;128: 1–28. doi:10.1086/716461
- 1660 50. US Census Bureau. Allegheny County, Pennsylvania - Census Bureau Profile. [cited 29 May
1661 2024]. Available:
1662 [https://data.census.gov/profile/Allegheny_County,_Pennsylvania?g=050XX00US42003#ra](https://data.census.gov/profile/Allegheny_County,_Pennsylvania?g=050XX00US42003#race-and-ethnicity)
1663 [ce-and-ethnicity](https://data.census.gov/profile/Allegheny_County,_Pennsylvania?g=050XX00US42003#race-and-ethnicity)
- 1664 51. Jakubowski A, Fox A. Defining Low-threshold Buprenorphine Treatment. *Journal of*
1665 *Addiction Medicine*. 2020;14: 95–98. doi:10.1097/ADM.0000000000000555
- 1666 52. Keane C, Egan JE, Hawk M. Effects of naloxone distribution to likely bystanders: Results of
1667 an agent-based model. *International Journal of Drug Policy*. 2018;55: 61–69.
1668 doi:10.1016/j.drugpo.2018.02.008
- 1669 53. Bazzi AR, Valasek CJ, Stamos-Buesig T, Eger WH, Harvey-Vera A, Vera CF, et al. Health,
1670 harm reduction, and social service providers’ perspectives on the appropriateness and
1671 feasibility of peer distribution of HIV self-test kits among people who use drugs. *Harm*
1672 *Reduct J*. 2024;21: 29. doi:10.1186/s12954-024-00950-x
- 1673 54. Hanson BL, Porter RR, Zöld AL, Terhorst-Miller H. Preventing opioid overdose with peer-
1674 administered naloxone: findings from a rural state. *Harm Reduct J*. 2020;17: 4.
1675 doi:10.1186/s12954-019-0352-0
- 1676 55. Gittens RA. Atlanta’s Pink Trap House: Reimagining the Black Public Sphere as an Aesthetic
1677 Community. *Theory & Event*. 2021;24: 434–455. doi:10.1353/tae.2021.0021

- 1678 56. Curry SR, Samuels GM, Cerven C, Dworsky A. Navigating Housing Instability and Substance
1679 Use: Hidden Tensions Facing Youth in Small Town America. *Journal of Social Service*
1680 *Research*. 2020;46: 361–378. doi:10.1080/01488376.2019.1575322
- 1681 57. Jawa R, Murray S, Blakemore S, Ventura AS, Hristova T, Wilder A, et al. Xylazine and
1682 Adulterants in the Evolving Drug Supply: Urgent Call for Responsive Education Models.
1683 *Substance Use & Addiction Journal*. 2024;45: 168–175.
1684 doi:10.1177/29767342241231114
- 1685 58. AIDS Institute, New York State Department of Health. New York State Technical Working
1686 Group on Resuscitation Training in Naloxone Provision Programs, 2016 Report. Available:
1687 [https://www.health.ny.gov/diseases/aids/general/opioid_overdose_prevention/docs/resu](https://www.health.ny.gov/diseases/aids/general/opioid_overdose_prevention/docs/resuscitation_training.pdf)
1688 [scitation_training.pdf](https://www.health.ny.gov/diseases/aids/general/opioid_overdose_prevention/docs/resuscitation_training.pdf)
- 1689 59. CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - DRUG OVERDOSE
1690 RESPONSE IMMUNITY, Act of Sep. 30, 2014. PL 2487, SB 1164.
- 1691 60. Carroll JJ, Ostrach B, Wilson L, Dunlap JL, Getty R, Bennett J. Drug induced homicide laws
1692 may worsen opioid related harms: An example from rural North Carolina. *International*
1693 *Journal of Drug Policy*. 2021;97: 103406. doi:10.1016/j.drugpo.2021.103406
- 1694 61. Jalal H, Burke DS. Carfentanil and the rise and fall of overdose deaths in the United States.
1695 *Addiction*. 2021;116: 1593–1599. doi:10.1111/add.15260
- 1696 62. Kornfield M. Naloxone supply issues threaten worsening drug overdose crisis. *The*
1697 *Washington Post*. 11 Aug 2021. Available:
1698 <https://www.washingtonpost.com/health/2021/08/11/naloxone-demand/>. Accessed 9
1699 Sep 2024.
- 1700 63. Schuler MS, Dick AW, Stein BD. Growing racial/ethnic disparities in buprenorphine
1701 distribution in the United States, 2007-2017. *Drug and Alcohol Dependence*. 2021;223:
1702 108710. doi:10.1016/j.drugalcdep.2021.108710
- 1703 64. Hansen H, Siegel C, Wanderling J, DiRocco D. Buprenorphine and methadone treatment
1704 for opioid dependence by income, ethnicity and race of neighborhoods in New York City.
1705 *Drug and Alcohol Dependence*. 2016;164: 14–21. doi:10.1016/j.drugalcdep.2016.03.028
- 1706 65. Nguyen T, Ziedan E, Simon K, Miles J, Crystal S, Samples H, et al. Racial and Ethnic
1707 Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During
1708 the COVID-19 Pandemic. *JAMA Netw Open*. 2022;5: e2214765.
1709 doi:10.1001/jamanetworkopen.2022.14765
- 1710 66. Lindsey JS, Frederick-Dyer K, Carr JJ, Cooke E, Allen LM, Omary RA. Modeling the
1711 Environmental and Financial Impact of Multi-dose vs. Single-dose Iodinated Contrast
1712 Media Packaging and Delivery Systems. *Academic Radiology*. 2023;30: 1017–1023.
1713 doi:10.1016/j.acra.2022.12.029

- 1714 67. Lee BY, Norman BA, Assi T-M, Chen S-I, Bailey RR, Rajgopal J, et al. Single versus multi-dose
1715 vaccine vials: An economic computational model. *Vaccine*. 2010;28: 5292–5300.
1716 doi:10.1016/j.vaccine.2010.05.048
- 1717 68. Neale J, Farrugia A, Campbell AN, Dietze P, Dwyer R, Fomiatti R, et al. Understanding
1718 preferences for type of take-home naloxone device: international qualitative analysis of
1719 the views of people who use opioids. *Drugs: Education, Prevention and Policy*. 2022;29:
1720 109–120. doi:10.1080/09687637.2021.1872499
- 1721 69. Payne ER, Stancliff S, Rowe K, Christie JA, Dailey MW. Comparison of Administration of 8-
1722 Milligram and 4-Milligram Intranasal Naloxone by Law Enforcement During Response to
1723 Suspected Opioid Overdose — New York, March 2022–August 2023. *MMWR Morb Mortal*
1724 *Wkly Rep*. 2024;73: 110–113. doi:10.15585/mmwr.mm7305a4
- 1725 70. Rock P, Slavova S, Westgate PM, Nakamura A, Walsh SL. Examination of naloxone dosing
1726 patterns for opioid overdose by emergency medical services in Kentucky during increased
1727 fentanyl use from 2018 to 2021. *Drug and Alcohol Dependence*. 2024;255: 111062.
1728 doi:10.1016/j.drugalcdep.2023.111062
- 1729 71. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid
1730 overdose crisis. *Curr Opin Psychiatry*. 2021;34: 344–350.
1731 doi:10.1097/YCO.0000000000000717
- 1732 72. Pennsylvania Department of Health, Office of Drug Surveillance and Misuse Prevention.
1733 Fatal and Non-Fatal Drug Overdose Surveillance Interactive Data Report. Available:
1734 [https://public.tableau.com/app/profile/pennsylvania.pdmp/viz/PennsylvaniaODSMPDrug](https://public.tableau.com/app/profile/pennsylvania.pdmp/viz/PennsylvaniaODSMPDrugOverdoseSurveillanceInteractiveDataReport/Contents)
1735 [OverdoseSurveillanceInteractiveDataReport/Contents](https://public.tableau.com/app/profile/pennsylvania.pdmp/viz/PennsylvaniaODSMPDrugOverdoseSurveillanceInteractiveDataReport/Contents)
- 1736 73. Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, et al. Reducing the
1737 harms of xylazine: clinical approaches, research deficits, and public health context. *Harm*
1738 *Reduct J*. 2023;20: 141. doi:10.1186/s12954-023-00879-7
- 1739 74. Van Der Meulen E, Chu SKH. “The Law Doesn’t Protect Me”: Examining the Effectiveness
1740 of Good Samaritan Drug Overdose Legislation. *Substance Use & Misuse*. 2022;57: 1392–
1741 1399. doi:10.1080/10826084.2022.2083173
- 1742 75. Latimore AD, Bergstein RS. “Caught with a body” yet protected by law? Calling 911 for
1743 opioid overdose in the context of the Good Samaritan Law. *International Journal of Drug*
1744 *Policy*. 2017;50: 82–89. doi:10.1016/j.drugpo.2017.09.010
- 1745 76. Ackermann E, Kievit B, Xavier J, Barbic S, Ferguson M, Greer A, et al. Awareness and
1746 knowledge of the Good Samaritan Drug Overdose Act among people at risk of witnessing
1747 an overdose in British Columbia, Canada: a multi-methods cross sectional study. *Subst*
1748 *Abuse Treat Prev Policy*. 2022;17: 42. doi:10.1186/s13011-022-00472-4

- 1749 77. Schneider KE, Park JN, Allen ST, Weir BW, Sherman SG. Knowledge of Good Samaritan
1750 Laws and Beliefs About Arrests Among Persons Who Inject Drugs a Year After Policy
1751 Change in Baltimore, Maryland. *Public Health Rep.* 2020;135: 393–400.
1752 doi:10.1177/0033354920915439
- 1753 78. Tanz LJ, Gladden RM, Dinwiddie AT, Miller KD, Broz D, Spector E, et al. Routes of Drug Use
1754 Among Drug Overdose Deaths — United States, 2020–2022. *MMWR Morb Mortal Wkly*
1755 *Rep.* 2024;73: 124–130. doi:10.15585/mmwr.mm7306a2
- 1756 79. Wagner KD, Koch B, Bowles JM, Verdugo SR, Harding RW, Davidson PJ. Factors Associated
1757 With Calling 911 for an Overdose: An Ethnographic Decision Tree Modeling Approach. *Am*
1758 *J Public Health.* 2021;111: 1281–1283. doi:10.2105/AJPH.2021.306261
- 1759 80. Ostrach B, Hixon V, Bryce A. “When people who use drugs can’t differentiate between
1760 medical care and cops, it’s a problem.” Compounding risks of law Enforcement
1761 Harassment & Punitive Healthcare Policies. *Health Justice.* 2024;12: 3.
1762 doi:10.1186/s40352-023-00256-3
- 1763 81. Bell A, Bennett AS, Jones TS, Doe-Simkins M, Williams LD. Amount of naloxone used to
1764 reverse opioid overdoses outside of medical practice in a city with increasing illicitly
1765 manufactured fentanyl in illicit drug supply. *null.* 2019;40: 52–55.
1766 doi:10.1080/08897077.2018.1449053
- 1767 82. Craine N, Hickman M, Parry JV, Smith J, McDonald T, Lyons M. Characteristics of injecting
1768 drug users accessing different types of needle and syringe programme or using secondary
1769 distribution. *Journal of Public Health.* 2010;32: 328–335. doi:10.1093/pubmed/fdp131
- 1770 83. Noroozi A, Mirzazadeh A, Hajebi A, Farhoudian A, Sharifi H, Higgs P, et al. Comparing
1771 profile of people who inject drugs (PWID) accessing different types of needle and syringe
1772 programs or secondary distribution in Kermanshah, Iran. *Journal of Substance Use.*
1773 2017;22: 304–309. doi:10.1080/14659891.2016.1195894
- 1774 84. Glass R, Hope VD, Njoroge J, Edmundson C, Smith J, McVeigh J, et al. Secondary
1775 distribution of injecting equipment obtained from needle and syringe programmes by
1776 people injecting image and performance enhancing drugs: England and Wales, 2012-15.
1777 *Drug and Alcohol Dependence.* 2019;195: 40–44. doi:10.1016/j.drugalcdep.2018.11.021
- 1778 85. Sarang A, Rhodes T, Platt L. Access to syringes in three Russian cities: Implications for
1779 syringe distribution and coverage. *International Journal of Drug Policy.* 2008;19: 25–36.
1780 doi:10.1016/j.drugpo.2007.11.008
- 1781 86. Fisher DG, Wilson H, Bryant J. Harm reduction knowledge and information exchange
1782 among secondary distributors in Sydney, Australia. *Drugs: Education, Prevention and*
1783 *Policy.* 2013;20: 67–73. doi:10.3109/09687637.2012.687793

- 1784 87. Russell E, Johnson J, Kosinski Z, Kaplan C, Barnes N, Allen S, et al. A scoping review of
1785 implementation considerations for harm reduction vending machines. *Harm Reduct J.*
1786 2023;20: 33. doi:10.1186/s12954-023-00765-2
- 1787 88. Yang C, Favaro J, Meacham MC. NEXT Harm Reduction: An Online, Mail-Based Naloxone
1788 Distribution and Harm-Reduction Program. *Am J Public Health.* 2021;111: 667–671.
1789 doi:10.2105/AJPH.2020.306124
- 1790 89. Russell E, Lovitch N. Compassionate Overdose Response Summit: Highlights and Key
1791 Takeaways. Pittsburgh, PA, USA: Health Management Associates; 2024 May. Available:
1792 [https://www.healthmanagement.com/wp-content/uploads/HMA-Report-Compassionate-](https://www.healthmanagement.com/wp-content/uploads/HMA-Report-Compassionate-Overdose-Response-Summit_5-1-FINAL.pdf)
1793 [Overdose-Response-Summit_5-1-FINAL.pdf](https://www.healthmanagement.com/wp-content/uploads/HMA-Report-Compassionate-Overdose-Response-Summit_5-1-FINAL.pdf)
- 1794 90. Marks C, Wagner KD. Supporting people responding to overdoses. *The Lancet Public*
1795 *Health.* 2022;7: e198–e199. doi:10.1016/S2468-2667(22)00011-1
- 1796 91. Shearer D, Fleming T, Fowler A, Boyd J, McNeil R. Naloxone distribution, trauma, and
1797 supporting community-based overdose responders. *International Journal of Drug Policy.*
1798 2019;74: 255–256. doi:10.1016/j.drugpo.2018.11.008
- 1799




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 9




Figure 13




Figure 1






Figure 10




Figure 11







Figure 12




Figure 8